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Clinical phenotyping and stroke subtyping 
In two discovery centers (Rotterdam, HPS) and three replication centers (Copenhagen, VISP, Portugal) data on 
subtypes was not available and these cohorts were only included in analyses of all ischaemic stroke and sex 
specific analyses. 
Statistical Analysis across studies 
Analysis was restricted to SNPs that met the QC criteria in at least six centers for the young stroke analysis as well 
as the LVD, CE, and SVD subtypes. All centres provided data for the all ischaemic stroke and sex specific 
analyses, so SNPs present in at least eight centers were considered for analysis. The number of SNPs remaining 
after QC in each analysis was approximately 2!4M, roughly corresponding to the SNPs from the HapMap II SNP 
set.  Genomic Inflation factor correction was used per center to correct for over-dispersion. After meta-analysis, 
statistical heterogeneity was evaluated using Cochran’s test (Q-test). Manhattan and QQ-plots were generated 
using the R statistical software package (http://www.R-project.org). Plots of the –log10(p-values) by genomic 
position for associations of statistical significance were generated using LocusZoom 
(http://csg.sph.umich.edu/locuszoom/). 
Discovery analysis 
Four of the discovery cohorts used ancestry-informative prinicipal components as covariates to correct for 
population stratification (ISGS/SWISS, GEOS, ASGC, BRAINS). Age and sex were included as covariates in two 
centres (ISGS/SWISS and BRAINS), sex was used as a covariate in one centre (MGH-GASROS) and one center 
used recruitment phase (1 or 2) as a covariate (GEOS). In all other centres no covariates were included.  
Replication analysis 
For all centers, SNPs were removed that failed testing for Hardy-Weinberg equilibrium at p<1x10-4. The cases 
from Edinburgh and Glasgow were from cohorts approximately 60 miles apart geographically. We therefore 
combined the cases and analysed against a common control set from the same geographical region (Lothian Birth 
Cohort 1936). Age and sex were included as covariates in four centres (RACE, WHI, Interstroke, GO-Darts) and 
ancestry-informative principal components were included in five centres (RACE, WHI, Interstroke, GO-Darts, 
VISP). 
Population Attributable Risks 
Population attributable risks were estimated using the following formula: 
!"#! ! !!""!!!! !" ! !! !" ! ! ! !  
where OR is the odds ratio and p is the prevalence of the risk allele. 
 
 
 
 
 
Supplementary Table 1: Description of conditional analysis regions used in analysis of established loci 
Gene Lead SNP Chromosome SNP  
Base Position 
Region from 
(recombination rate peak*) 
Region to 
(recombination rate peak) 
HDAC9 rs2107595 7 19,015,913 18,900,000 
(0!3 cM) 
19,100,000 
(0!7 cM) 
ZFHX3 rs879324 16 71,626,169 71,490,000 
(0!5 cM) 
71,690,000 
(0!3 cM) 
PITX2 rs6843082 
 
4 111,937,516 111,690,000 
(0!6 cM) 
111,955,000 
(0!4 cM) 
*approximate recombination rate, as measured in centimorgans (cM) for HapMap II CEU population.  
 
 
Supplementary Table 2: Description of SNP associations in METASTROKE for replicated SNPs from 
original publication (where different to METASTROKE top SNP) 
  
 
 
 
 
 
 
 
RA, risk allele; RAF, risk allele frequency; CE, cardioembolic stroke; LVD, large vessel disease; OR, odds ratio 
 
 
Supplementary Table 3: Description of associations with established cardioembolic stroke SNPs in 
prospective population based cohort studies 
Gene No! cases No! controls SNP RA RAF Subtype OR 
(95% CI) 
P 
PITX2 378 16745 rs6843082 G 0!22 CE 1!26 (1!05–1!52) 0!013 
ZFHX3 378 16745 rs879324 A 0!17 CE 1!23 (0!98–1!55) 0!079 
RA, risk allele; RAF, risk allele frequency; CE, cardioembolic stroke; OR, odds ratio 
 
Gene CHR BP SNP RA RAF Subtype 
OR 
(95% CI) P 
 
HDAC9 
 
7 
18,998,460 
 
 
rs11984041 A 
 
0!10 LVD 
1!35 
(1!21–1!50) 2!6x10
–8 
 
PITX2 
 
4 
111,929,618 
 
 
rs2200733 
 
A 
 
0!13 CE 
1!34 
(1!23–1!46) 7.0x10
-11 
 
ZFHX3 
 
16 
71,609,121 
 
rs2106261 
 
A 
 
0!19 CE 
1!23 
(1!14–1!33) 6.2x10
-8 
Supplementary Table 4: Power Calculations of sample size required to achieve 80% power to replicate 
SNPs from discovery phase in Replication cohorts 
Subtype SNP RAF OR in discovery 
Sample size 
required for 80% 
power to replicate* 
No. cases in 
replication 
cohort 
IS rs225132 0.82 1.12 6054 13347 
IS rs17696736 0.42 1.10 4647 13347 
IS rs16851055 0.81 1.12 5794 13347 
CE rs6763538 0.04 1.47 1448 2388 
LVD rs7937106 0.16 1.68 232 2434 
LVD rs556621 0.33 1.20 1360 2434 
SVD rs7407640 0.21 1.23 1359 1993 
SVD rs13407662 0.04 1.95 412 1993 
FS rs7432308 0.15 1.16 3427 5948 
FS rs2238151 0.66 1.13 3100 5948 
YS rs12703165 0.82 1.20 2293 7407 
YS rs4875812 0.15 1.16 1879 7407 
*calculations based on OR and RAF from discovery phase, assuming at least twice as many controls than cases. P-
value for replication set at p<0.0042 corresponding to Bonferonni corrected type 1 error <5% for the 12 SNPs 
tested.  
LVD, large vessel disease; CE, cardioembolic stroke; IS, all ischaemic stroke; SVD, small vessel disease; FS, 
female stroke; YS, young stroke; RAF, risk allele frequency; OR, odds ratio;  
  
 (a)-(d) clockwise from top left: (a) QQ-plot of all SNPs in all ischaemic stroke analysis after removal of SNPs 
from 9p21, HDAC9, ZFHX3, and PITX2 loci (inflation factor=1.040); (b) QQ-plot of remaining SNPs from large 
vessel disease phenotype after removal of SNPs from HDAC9 and 9p21 loci (inflation factor=1.036); (c) QQ-plot 
of all SNPs from small vessel disease phenotype (inflation factor=1.024); (d) QQ-plot of remaining SNPs from 
cardioembolic stroke phenotype after removal of SNPs from PITX2 and ZFHX3 loci (inflation factor=1.027). 
 
  
Supplementary Figure 1 - QQ-plots for main analyses after removal of known loci 
 
Supplementary Figures 2-13 - Forest Plots of 12 SNPs selected for replication in the 18 replication 
populations 
 
 
 
 
 
 
 
  
 
 
 
Note: Dundee known otherwise as GO-Darts. 
 
 
Supplementary Table 4: Proportion of stroke cases with investigations performed in the discovery cohorts.  
Cohort 
Number of 
Cases 
Brain imaging with CT 
or MRI (%) MRI (%) ECG (%) Echocardiographic Imaging (%) Extracranial cerebral artery imaging (%) 
ARIC 385 98 - - - - 
ASGC 1162 97.4 43.0 59.6 20.0 5.0 
BRAINS* 387 100 30.8 35.4 46.5 90.4 
CHS 454 94.5 31.3 - - - 
deCODE 2391 100 - 100 - 100 
FHS 171 96.5** 75.4 100 70.2 84.8 
GEOS 448 100 89.5 86.4 77.7 90.4 
HPS 578 - - - - - 
HVH 566 96.5 32.7 - 44.9 70.1 
ISGS / SWISS 1070 100 83 89 76 85 
Milano 372 100 86.7 100 20.0 100 
MGH-GASROS* 533 100 60 47 54 100 
Rotterdam 367 100 - 100 - - 
WTCCC2-Edinburgh (UK) * 713 100 25.9 100 36.9 93.8 
WTCCC2- London (UK) * 1288 100 50.5 100 43.1 98.0 
WTCCC2- Oxford (UK) * 884 100 26.9 100 26.4 100 
WTCCC2- Munich* 1228 100 83 100 80 100 
ARIC=The Atherosclerosis Risk in Communities study. ASGC=Australian Stroke Genetics Collabarative. BRAINS=Bio-Repository of DNA in stroke. CHS=Cardiovascular 
Health Study. FHS=Framingham Heart Study. GEOS=Genetics of Early-Onset Stroke. HPS=Heart Protection Study. HVH=The Heart and Vascular Health Study. 
ISGS/SWISS=The Ischemic Stroke Genetics Study/Sibling with Ischaemic Stroke Study. MGH-GASROS=The MGH Genes Affecting Stroke Risk and Outcome Study. 
WTCCC2=The Wellcome Trust Case-Control Consortium II. CT=Computed Tomography. MRI=Magnetic Resonance Imaging. ECG=Electrocardiogram. “-“=data not 
available, not recorded or performed only as clinically indicated. Extracranial cerebral arterial imaging includes carotid and vertebral artery ultrasound, or computed 
tomographic angiography, or magnetic resonance angiography. * values given are for individuals prior to genotypic QC steps. **Persons without imaging had autopsy-
verified stroke.  
 
 
!
Supplementary Table 5: Discovery Cohort Characteristics  !
 
ARIC=The Atherosclerosis Risk in Communities study. ASGC=Australian Stroke Genetics Collabarative. BRAINS=Bio-Repository of DNA in stroke. CHS=Cardiovascular 
Health Study. FHS=Framingham Heart Study. GEOS=Genetics of Early-Onset Stroke. HPS=Heart Protection Study. HVH=The Heart and Vascular Health Study. 
ISGS/SWISS=The Ischemic Stroke Genetics Study/Sibling with Ischaemic Stroke Study. MGH-GASROS=The MGH Genes Affecting Stroke Risk and Outcome Study. 
 Sample size Age (mean ± SD) Male Gender (%) 
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ARIC 385 63 93 31 8803 57.3 ± 5.3 55.3 ± 6.2 57.4 ± 
5.0 
57.8 ± 4.3 54.1 ± 5.7 60.3 58.7 62.4 58.1 46.5 98 
ASGC 1162 310 240 421 1244 72.9 ± 
13.2 
77.5 ± 
13.1 
81.2 ± 
12.1 
73.2 ± 12.3 70.2 ± 
12.1 
59.2 57.4 50.4 68.7 50.2 100 
BRAINS 361 97 29 120 444 74.4  ± 
14.2 
73.9  
±15.4 
15.4 
 
74.8 
±11.7 
77.7 ± 11.9 65+a 55.9 52.5 51.6 52.5 35.8 100 
CHS 454 73 147 - 2817 81.6 ± 
6.11 
74.3 ± 6.1 73.6 ± 
5.7 
- 85.8 ± 
5.64 
45.0 34.2 42.9 - 45.0 94.5 
deCODE 2391 240 399 255 26970 73.3 ± 
12.1 
68.8 ± 
10.2 
71.2 ± 
10.9 
70.5 ± 9.3 57.3 ± 
21.4 
55.0 56.5 60.4 61.2 38.0 100 
FHS 171 - 48 - 4164 79.6 ±10.5 - 83.3 ± 
9.1 
- 71.9± 
11.9 
43.3 - 39.6 - 45.1 96.5 
GEOS 448 54 90 37 498 41.0 ± 7.0 44.3 ± 4.1 39.2 ± 
7.5 
45.2 ± 2.7 39.5 ± 6.7 61.4 72.2 58.9 67.6 56.6 100 
HPS 578 - - - 468 64.9 ± 7.5 - - - 59.2 ± 9.3 75.0 - - - 67.0 - 
HVH 566 173 88 61 1290 69.2 ± 8.6 67.6 ± 9.3 71.1 ± 
7.7 
67.9 ± 9.4 66.6 ± 9.1 33.7 32.9 33.0 44.3 47.7 97.2 
ISGS/ SWISS 1070 201 247 229 2329 66.5 ± 
13.6 
64.6 ± 
13.6 
67.8 ± 
14.4 
69.1 ± 12.2 64.8 ± 
12.6 
57.2 60.3 53.7 59.2 48.0 100 
MGH-
GASROS 
516 38 169 95 1202 66.7 ± 
14.5 
65.7 ± 
14.2 
66.2 ± 
13.2 
66.8 ± 13.8 47.5 ± 8.5 60.3 63.2 68.0 
 
58.9 59.1 100 
Milano 372 65 25 74 407 
57.4 ± 
15.6 
56.2 ± 
17.3 
59.9 ± 
15.0 63.5 ± 10.9 50.8 ± 8.1 62.8 56.7 68.0 76.0 87.7 100 
Rotterdam 367 - - - 5396 70.8 ± 7.5 - - - 69.0 ± 9.0 45.2 - - - 40.3 100 
WTCCC2-
Munich 
1174 106 330 346 797 66.7 ± 
12.9 
65.1±12.9 
 
71.7± 
12.1 
65.7 ± 10.8 62.7 ± 
10.9 
61.9 72.6 52.1 70.7 51.4 100 
WTCCC2-UK 2374 474 460 498 5175 72.2 ± 12.5 
75.4 ± 
12.5 
69.6 ± 
11.7 68.2 ± 10.8 ~52
b 53.8 52.3 62.1 66.2 49.5 100 
WTCCC2=The Wellcome Trust Case-Control Consortium II. IS=Ischaemic Stroke. SVD=small vessel disease. LVD=large vessel disease. CE=cardioembolic stroke; “-
“=information not available or not relevant. a All controls were aged 65 years or older at the time of genotyping. No further information was available. b The approximate age 
at genotyping of the 2738 controls from the 1958 Birth Cohort. Age was not available for the remaining controls.
Ascertainment and clinical assessment of participants in discovery studies 
Participating studies were approved by relevant institutional review boards, and all participants gave 
informed consent for study participation, including genetic research. !
The Atherosclerosis Risk in Communities Study (ARIC) 
The ARIC study is a prospective population-based study of atherosclerosis and clinical atherosclerotic 
diseases in 15,792 men and women, including 11,478 non-Hispanic white participants, drawn from 4 
U.S. communities (Suburban Minneapolis, Minnesota; Washington County, Maryland; Forsyth 
County, North Carolina, and Jackson, Mississippi). In the first three communities, the sample reflects 
the demographic composition of the community. In Jackson, only black residents were enrolled. 
Ancestry was self-reported during an interview. Over 99% self-identified as either white or black. Only 
self-identified whites were included in the analyses.1 
Hospitalized strokes that occurred by December 31, 2007 (median follow-up, 18.7 years) were 
included in the analyses. During annual telephone contacts, trained interviewers asked each ARIC 
participant to list all hospitalizations during the past year. Hospital records for any hospitalizations 
indentified were then obtained. Moreover, all local hospitals annually provided lists of stroke 
discharges (International Classification of Diseases, Ninth Revision, Clinical Modification codes 430 
to 438), which were surveyed for ARIC participant discharges. Details on quality assurance for 
ascertainment and classification of stroke are described elsewhere.2 
http://hyper.ahajournals.org/content/57/2/167.full - ref-10 Briefly, the stroke diagnosis was assigned 
according to criteria adapted from the National Survey of Stroke.3 Strokes secondary to trauma, 
neoplasm, hematologic abnormality, infection, or vasculitis were excluded, and a focal deficit lasting 
<24 hours was not considered to be a stroke. Out-of-hospital stroke was not ascertained and validated; 
thus, these potential stroke events are not included. Strokes were classified into hemorrhagic stroke 
(subarachnoid and intracerebral hemorrhage) and ischemic stroke (thrombotic and embolic brain 
infarction). A stroke was classified as ischemic when a brain CT or MRI revealed acute infarction and 
showed no evidence of hemorrhage. All definite ischemic strokes were further classified as lacunar, 
nonlacunar thrombotic, or cardioembolic on the basis of the recorded neuroimaging results. A stroke 
was classified as “lacunar” when 2 criteria were met: (1) typical location of the infarct (basal ganglia, 
brain stem, thalamus, internal capsule, or cerebral white matter); and (2) infarct size of !2 cm or 
unstated size.4 Definite or probable “cardioembolic” stroke required either (1) autopsy evidence of an 
infarcted area in the brain and a source of possible cerebral emboli in a vessel or the presence of an 
embolus in the brain or (2) medical record evidence of a possible noncarotid source of embolus such as 
moderate or greater valvular heart disease, atrial fibrillation, cardiac or arterial procedure (eg, cardiac 
catheterization, open heart surgery, cerebral angiography, and carotid endarterectomy), or intracardiac 
thrombus. Definite or probable ischemic strokes that were not classified as lacunar or cardioembolic, 
including atherothrombotic and unclassified thrombotic strokes, were labeled “nonlacunar.” 
Hemorrhagic strokes identified by ARIC were censored at the time of their occurrence. 
Australian Stroke Genetics Collaborative (ASGC) 
ASGC stroke cases comprised European-ancestry stroke patients admitted to four clinical centres 
across Australia (The Neurosciences Department at Gosford Hospital, Gosford, New South Wales 
(NSW); the Neurology Department at John Hunter Hospital, Newcastle, NSW; The Queen Elizabeth 
Hospital, Adelaide ; and the Royal Perth Hospital, Perth) between 2003 and 2008. Stroke was defined 
by WHO criteria as a sudden focal neurologic deficit of vascular origin, lasting more than 24 hours and 
confirmed by imaging such as computerised tomography (CT) and/or magnetic resonance imaging 
(MRI) brain scan. Other investigative tests such as electrocardiogram, carotid doppler and trans-
oesophageal echocardiogram were conducted to define IS mechanism as clinically appropriate. Cases 
were excluded from participation if aged <18 years, diagnosed with haemorrhagic stroke or transient 
ischemic attack rather than IS, or were unable to undergo baseline brain imaging. Based on these 
criteria, a total of 1230 IS cases were included in the current study. IS subtypes were assigned using 
TOAST criteria, based on clinical, imaging and risk factor data. 
ASGC controls were participants in the Hunter Community Study (HCS), a population-based cohort of 
individuals aged 55-85 years, predominantly of European Caucasian ancestry and residing in the 
Hunter Region, NSW, Australia. Detailed recruitment methods for the HCS have been previously 
described 31. Briefly, participants were randomly selected from the NSW State electoral roll and 
contacted by mail between 2004 and 2007. Consenting participants completed five detailed self-report 
questionnaires and attended the HCS data collection centre, at which time a series of clinical measures 
were obtained. A total of 1280 HCS participants were genotyped for the current study. 
 All study participants gave informed consent for participation in genetic studies. Approval for the 
individual studies was obtained from relevant institutional ethics committees.  
Bio-Repository of DNA in Stroke (BRAINS) 
The Bio-Repository of DNA in Stroke (BRAINS) is an international study recruiting highly 
phenotyped patients with stroke. For the purposes of the current work all patients were Caucasians. 
Diagnosis of stroke was confirmed using positive imaging (MRI or CT) and ischemic stroke subtypes 
were assigned using TOAST criteria, based on clinical, imaging and risk factor data. Controls were 
European-Ancestry, stroke-free participants from the shared WTCCC controls, a prospectively 
collected cohort of individuals born in 1958 (1958 Birth Cohort). The cohort has been described in 
detail elsewhere.5 
Cardiovascular Health Study (CHS)   
The CHS is a population-based cohort study of risk factors for coronary heart disease (CHD) and 
stroke in adults !65 years conducted across four field centers in the United States.6 The original 
predominantly white cohort of 5,201 persons (4,964 whites) was recruited in 1989-1990 from a random 
sample of people on Medicare eligibility lists and an additional 687 African-Americans were enrolled 
subsequently (1992-93) for a total sample of 5,888.  Race was determined by self-identification at 
interview. In addition to the 5 categories used in the ARIC study, participants were also asked a second 
question as to whether they considered themselves to be of Hispanic origin. To reduce the possibility of 
confounding by population structure, these analyses were limited to participants of self-described 
European-ancestry. The study sample for these analyses includes participants who were free of CVD at 
baseline, had blood samples drawn at their baseline examination, consented to genetic testing, had 
DNA available, and had successful genome-wide genotyping assay. 
Participants were examined annually from enrollment to 1999, and since then continue to be under 
surveillance for stroke. Since baseline, participants have also been contacted twice a year to identify 
potential cardiovascular events, including stroke. In addition, all hospitalizations were screened for 
potential stroke events. For suspected events, information was collected from the participant or next of 
kin, from medical records, and, if needed, from the participant's physician. When available, CT and/or 
MRI scans or reports were reviewed centrally. Final adjudication of the occurrence of stroke, stroke 
types, and subtypes was undertaken by vascular neurologists at a consensus conference using all 
available information. 
Strokes were classified as ischemic if there was imaging (CT or MRI within 4 weeks), surgical or 
autopsy evidence excluding a hemorrhage, or in the absence of such direct evidence (in <10% of cases 
in FHS and Rotterdam, none in CHS) if the preponderance of indirect evidence (e.g. deficit limited to 
one limb or completely resolved within 72 hours, atrial fibrillation in persons not on anticoagulants) 
suggested the event was an ischemic rather than a hemorrhagic stroke. A stroke was classified as 
hemorrhagic if there was imaging, surgical, lumbar puncture or autopsy evidence of hemorrhage, and 
in the absence of direct evidence to the contrary, when the participant lost consciousness permanently 
or died within hours after onset of focal signs. The stroke type was defined as unknown if there was 
insufficient information available to categorize the event as ischemic or hemorrhagic. All ischemic and 
hemorrhagic strokes and strokes of unknown type were included in the analyses of total stroke with one 
exception: subarachnoid hemorrhages (n=28 across all studies) were excluded from these analyses 
since the heritability, risk factors and pathophysiologic mechanisms underlying subarachnoid 
hemorrhages are distinctly different from other stroke subtypes. Persons with a subarachnoid 
hemorrhage were censored at the time of the event. 
Only known ischemic strokes were included in the analysis of ischemic stroke. In secondary analyses 
we related those SNPs which reached genome-wide significance in our initial GWAS to the specific 
ischemic stroke subtype of atherothrombotic stroke, also called atherothrombotic brain infarction 
(ABI). We used the best available definitions of definite and possible ABI in each cohort; both large 
artery atherosclerotic strokes and small-vessel or lacunar strokes were included in this phenotype, 
events known to be cardioembolic were excluded. For the analysis of ABI, participants were censored 
when they developed an alternative type of stroke. 
Framingham Heart Study (FHS) 
The FHS is a three-generation, single-site, community-based, ongoing cohort study that was initiated in 
1948 to investigate prospectively the risk factors for CVD including stroke. It now comprises 3 
generations of participants (N=10,333): the Original cohort followed since 1948;7 their Offspring and 
spouses of the Offspring, followed since 1971;8 and children from the largest Offspring families 
enrolled in 2000 (Gen 3).9 Gen 3 participants were not included in this analysis since they are young 
(mean age 40±9 years) and few have suffered strokes. The Original cohort enrolled 5209 men and 
women who comprised two-thirds of the adult population then residing in Framingham, MA. Survivors 
continue to receive biennial examinations. The Offspring cohort comprises 5124 persons (including 
3514 biological offspring) who have been examined approximately once every 4 years. The population 
of Framingham was virtually entirely white (Europeans of English, Scots, Irish and Italian descent) in 
1948 when the Original cohort was recruited. At the initial examination participants were asked for 
country of birth and whether or not they had any Italian ancestry. At a later examination (the 8th) the 
Offspring cohort participants were asked to identify their race from the following choices: Caucasian or 
white, African-American or black, Asian, Native Hawaiian or other Pacific Islander, American Indian 
or Alaska native or ‘prefer not to answer’. They were also asked to identify their ethnicity as either 
‘Hispanic or Latino’ or neither. Almost all the FHS Original and Offspring participants are 
white/Caucasian and none were excluded from the discovery cohort.  
At each clinic exam, participants receive questionnaires, physical examinations and laboratory testing; 
between examinations they remain under surveillance (regardless of whether or not they live in the 
vicinity) via physician referrals, record linkage and annual telephone health history updates. Incident 
strokes have been identified since 1948 through this ongoing system of FHS clinic and local hospital 
surveillance and methods used have been detailed previously;10-12 they include review of medical 
records and collaboration with local general practitioners, emergency rooms and imaging facilities. If a 
participant saw a physician or was admitted to the hospital, visited an emergency room or obtained any 
brain imaging between biennial examinations for symptoms suggestive of TIA or stroke, a stroke 
neurologist from the Heart Study attempted to visit the person within 48 hours and recorded a complete 
history and neurological examination; this was repeated at 1, 3 and 6 months. All medical records from 
practitioners, hospitals, imaging centers, rehabilitation centers and nursing homes were procured for 
review. A panel of 3 investigators (at least 2 neurologists) adjudicated the diagnosis of stroke and 
determined stroke subtype in each case based on the Framingham evaluations and external records. The 
recruitment of Original and Offspring cohort participants at FHS had occurred long before the DNA 
collection with the result that a large number of stroke events in the FHS (although ascertained 
prospectively) were prevalent at the time of DNA collection and were excluded from these analyses. 
While this reduced the sample size from FHS, the meta-analyses presented here focused on incident 
events. 
Strokes were classified as ischemic if there was imaging (CT or MRI within 4 weeks), surgical or 
autopsy evidence excluding a hemorrhage, or in the absence of such direct evidence (in <10% of cases 
in FHS and Rotterdam, none in CHS) if the preponderance of indirect evidence (e.g. deficit limited to 
one limb or completely resolved within 72 hours, atrial fibrillation in persons not on anticoagulants) 
suggested the event was an ischemic rather than a hemorrhagic stroke. A stroke was classified as 
hemorrhagic if there was imaging, surgical, lumbar puncture or autopsy evidence of hemorrhage, and 
in the absence of direct evidence to the contrary, when the participant lost consciousness permanently 
or died within hours after onset of focal signs. The stroke type was defined as unknown if there was 
insufficient information available to categorize the event as ischemic or hemorrhagic. All ischemic and 
hemorrhagic strokes and strokes of unknown type were included in the analyses of total stroke with one 
exception: subarachnoid hemorrhages (n=28 across all studies) were excluded from these analyses 
since the heritability, risk factors and pathophysiologic mechanisms underlying subarachnoid 
hemorrhages are distinctly different from other stroke subtypes. Persons with a subarachnoid 
hemorrhage were censored at the time of the event. 
Only known ischemic strokes were included in the analysis of ischemic stroke. In secondary analyses 
we related those SNPs which reached genome-wide significance in our initial GWAS to the specific 
ischemic stroke subtype of atherothrombotic stroke, also called atherothrombotic brain infarction 
(ABI). We used the best available definitions of definite and possible ABI in each cohort; both large 
artery atherosclerotic strokes and small-vessel or lacunar strokes were included in this phenotype, 
events known to be cardioembolic were excluded. For the analysis of ABI, participants were censored 
when they developed an alternative type of stroke. A lacunar stroke was diagnosed based on either 
clinical presentation of a typical lacunar syndrome, or a clinical picture compatible with a lacunar 
lesion and imaging showing a small ischemic lesion in the territory of the deep penetrating arteries. An 
ischemic stroke was categorized as cardioembolic if there was evidence of a cardiac or aortic source of 
embolization based on the clinical presentation, brain imaging and review of all available cardiac 
assessments including ECG, echocardiography and cardiac monitoring. 
deCODE Genetics 
Cases, irrespective of age, were identified from a registry of individuals diagnosed with ischemic 
stroke or TIA at Landspitali University Hospital in Reykjavik, the only tertiary referral centre in 
Iceland, during the years 1993 to 2006. The ischemic stroke or TIA diagnoses were based on standard 
WHO criteria and imaging evidence (either CT or MRI), and were clinically confirmed by 
neurologists. Eligible patients who survived the stroke were invited to participate the genetic study, 
either by attending a recruitment centre for deCODE’s genetic studies, or they were visited at their 
home by a study nurse. Control subjects were participants from a large variety of genetic programs at 
deCODE. Individuals with confirmed stroke (identified by cross-matching with hospital lists), who had 
participated in genetic studies other than those of cardiovascular diseases (CVD) (but not participated 
in CVD studies) were excluded as controls. 
The Genetics of Early Onset Stroke (GEOS) Study, Baltimore, USA 
GEOS is a population-based case-control study designed to identify genes associated with early-onset 
stroke in patients with first-ever ischemic stroke aged 15-49 years from the greater Baltimore-
Washington area between 1992 and 2008.  Only patients of European descent are included in this meta-
analysis.  Cases were identified through discharge surveillance from 59 participating hospitals and 
direct physician referral from a defined geographic region. Abstracted medical records were reviewed 
and adjudicated for ischemic stroke subtype by two neurologists, with discrepancies resolved by a third 
neurologist. Controls with no history of ischemic stroke were identified through random digit dialing 
and were frequency-matched to cases based on sex, age, geographic location and, during the later study 
periods, ethnicity. 
Heart Protection Study (HPS) 
The Heart Protection Study (HPS) was a large randomized trial involving individuals at increased risk 
of vascular events. Between 1994-1997 20,536 men and women aged 40-80 years were recruited from 
69 collaborating hospitals in the United Kingdom (with ethics committee approval). Participants were 
eligible for inclusion provided they had non-fasting blood total cholesterol concentrations of at least 
135 mg/dL (3.5 mmol/L) and either a previous diagnosis of coronary disease, ischemic stroke, other 
occlusive disease of non-coronary arteries, diabetes mellitus, or (if were men 65 years or older) treated 
hypertension. None of them was on statin therapy. At the initial screening visit, all participants 
provided written consent and began a “run-in” phase involving 4 weeks of placebo followed by 4 to 6 
weeks of 40 mg simvastatin daily, after which compliant and eligible individuals were randomly 
allocated 40 mg simvastatin daily or matching placebo for approximately 5 years. Individuals entering 
HPS with a clinical diagnosis of ischemic stroke were used as cases in the METASTROKE study. 
Individuals entering HPS with pre-existing diabetes but no history of cerebrovascular disease, coronary 
heart disease or peripheral vascular disease were used as controls.   
The Heart and Vascular Health Study (HVH) 
The setting for this study was Group Health (GH), a large integrated health care system in western 
Washington State.  Data were utilized from an ongoing case-control study of incident myocardial 
infarction (MI) and stroke cases with a shared common control group.  Methods for the study have 
been described previously 13-15 and are briefly summarized below. The study was approved by the 
human subjects committee at GH, and written informed consent was provided by all study participants. 
All study participants were GH members and aged 30-79 years. MI and stroke cases were identified 
from hospital discharge diagnosis codes and were validated by medical record review. Controls were a 
random sample of GH members frequency matched to MI cases on age (within decade), sex, treated 
hypertension, and calendar year of identification. The index date for controls was a computer-generated 
random date within the calendar year for which they had been selected.  For stroke cases, the index 
date was the date of admission for the first acute stroke. Participants were excluded if they were recent 
enrolees at GH, had a history of prior stroke, or if the incident event was a complication of a procedure 
or surgery. 
Trained medical record abstractors collected eligibility and risk factor information from a review of the 
GH medical record using only data available prior to the index date and through a telephone interview.  
Medication use was ascertained using computerized GH pharmacy records.  A venous blood sample 
was collected from all consenting subjects, and DNA was extracted from white blood cells using 
standard procedures. 
Diagnostic criteria for ischemic stroke were adopted from the Cardiovascular Health Study.16 These 
criteria included (1) rapid onset of neurologic deficit or subarachnoid hemorrhage, (2) deficit persisting 
for longer than 24 hours unless computed tomography or magnetic resonance imaging show evidence 
of permanent damage, and (3) no underlying brain trauma, tumor, or infection to cause symptoms. 
These analyses were limited to ischemic stroke cases, namely those satisfying 1 or more of the 
following criteria:  (a) Focal deficit, without evidence of blood on CT or MRI, (b) Focal deficit, with 
mottled appearance in the appropriate location on CT, or (c) surgery or autopsy evidence of infarction. 
Among ischemic strokes, the subtypes were defined as follows: 
Lacunar stroke (“SVD”) required either: (a) CT/MRI demonstrates a deep area of infarction (decreased 
density) less than 2 cm. across, or (b) A normal CT, but the clinical syndrome is typical of a lacunar 
infarction, that is: a pure motor stroke, a pure sensory stroke, hemiparesis plus ataxia, or dysarthria plus 
a clumsy hand. Embolic stroke (“CE”) required either (a) a recognized source of emboli such as atrial 
fibrillation, endocarditis, mitral stenosis, thrombus in heart, recent MI or cardiac surgery, or (b) a 
mottled appearance consistent with infarction on the CT. Atherosclerotic infarction (“LAA”) when 
there is no apparent source of emboli or evidence of lacunar infarction and there is evidence of large 
vessel atherosclerosis by carotid ultrasound or angiography.   
The Ischemic Stroke Genetics Study (ISGS)/ Siblings With Ischemic Stroke Study (SWISS) 
The Siblings with Ischemic Stroke Study (SWISS) is a multicenter affected sibling pair study enrolling 
probands with ischemic stroke at 66 US medical centers and 4 Canadian medical centers.17 All 
probands are adult men and women over the age of 18 years diagnosed with ischemic stroke confirmed 
by a study neurologist on the basis of history, physical examination and CT or MR imaging of the 
brain. Additionally all probands were required to have at least one living sibling with a history of 
stroke. Siblings were enrolled using proband-initiated contact or direct contact when permitted by 
Institutional Review Boards. 18  Clinical exclusion criteria mirrored that in ISGS.  Concordant siblings 
had their diagnosis of ischemic stroke confirmed by review of medical records by a central vascular 
neurology committee. Subtype diagnoses were assigned to the index strokes of probands and 
concordant siblings according to TOAST criteria. 19  
Readily available US controls were utilized, including stroke-free participants from the Baltimore 
Longitudinal Study of Aging and the National Institute of Neurological Diseases and Stroke 
neurologically normal control series taken from the Coriell Cell Repositories. All controls had been 
previously genotyped and described in detail elsewhere. 
The Ischemic Stroke Genetic Study (ISGS) is a multicenter study where inpatient cases were recruited 
from five United States academic medical centers.20 Cases are adult men and women over the age of 18 
years diagnosed with first-ever ischemic stroke confirmed by a study neurologist on the basis of 
history, physical examination and CT or MR imaging of the brain who were enrolled within 30 days of 
onset of stroke symptoms. Cases exclusion criteria include: a mechanical aortic or mitral valve at the 
time of the index ischemic stroke, central nervous system vasculitis, bacterial endocarditis, cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 
Fabry disease, homocystinuria, mitochondrial encephalopathy with lactic acidosis and stroke-like 
episodes (MELAS), or sickle cell anemia. Stroke severity at enrollment was assessed using the NIH 
Stroke Scale with the diagnostic evaluation including head CT (95%) or MRI (83%), 
electrocardiography (92%), cervical arterial imaging (86%), and echocardiography (74%). Medical 
records from all cases were centrally reviewed by a vascular neurology committee and assigned 
ischemic stroke subtype diagnoses according to criteria from the Trial of ORG10172 (TOAST), the 
Oxfordshire Community Stroke Project, and the Baltimore-Washington Young Stroke Study.  
 
The MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS) 
Cases were all consecutive patients aged ! 18 years presenting with ischemic stroke and admitted to 
the Massachusetts General Hospital (MGH) Stroke Unit through the Emergency Department, or 
evaluated in  the MGH Neurology outpatient clinics, as well as on the inpatient Medical and Vascular 
Surgical services from January 2003 to July 2008. Only patients of European ancestry (confirmed by 
principal component analysis using genome-wide SNP data) were included in the present analysis. 
Ischemic stroke was defined as either (1) a radiographically proven (head CT or MRI) infarct 
associated with the appropriate clinical stroke syndrome, or (2) a fixed neurological deficit persisting 
more than 24 hours, consistent with a vascular pattern of involvement and without radiographic 
evidence of demyelinating disease, or other non-vascular structural disease. Patients with specific 
vascular disorders (vasculitis, subacute bacterial endocarditis, fibromuscular dysplasia, vasospasm) 
were excluded from the study.  All subjects were evaluated by a neurologist upon presentation and 
provided informed consent.  Clinical and laboratory data were collected during the admission for 
qualifying ischemic stroke event.  Diagnostic work-up included: head CT (100%), brain MRI (90%), 
cervical and intracranial vessel imaging using CTA or MRA (75%), carotid and/or transcranial 
ultrasound (24%), echocardiography (86%), and Holter monitoring (16%). Controls were recruited 
among the stroke-free adults presenting to the MGH outpatient clinics and matched with the stroke 
cases on the basis of age, sex and ancestry information obtained from principal component analysis of 
GWAS data. 
Milano 
This study Includes consecutive Italian patients referred to Besta Institute from 2000 to 2009 with 
stroke and included in the Besta Cerebrovascular Diseases Registry (CEDIR). Ischemic stroke cases, 
first ever or recurrent, confirmed on brain imaging, were selected for this study. All cases were of self 
reported Caucasian ancestry and had clinically relevant diagnostic workup performed. All cases were 
phenotyped by an experienced stroke neurologist according to TOAST criteria, based on relevant 
clinical imaging and available information on cardiovascular risk factors. Controls are Italian 
individuals enrolled within the PROCARDIS Study, with no personal or sibling history of coronary 
heart disease before age 66 years. 
Rotterdam 
The Rotterdam Study is a population-based cohort study among inhabitants of a district of Rotterdam 
(Ommoord), The Netherlands, and aims to examine the determinants of disease and health in the 
elderly with a focus on neurogeriatric, cardiovascular, bone, and eye disease.21 In 1990-1993, 7,983 
persons participated and were re-examined every 3 to 4 years. 
After enrollment in the Rotterdam Study, participants are continuously monitored for incident stroke 
through automated linkage of the study database with files from general practitioners. Nursing home 
physicians' files and files from general practitioners of participants who moved out of the district are 
scrutinized as well. Additional information is obtained from hospital records. Potential strokes are 
reviewed by research physicians and verified by an experienced stroke neurologist. Stroke is defined as 
rapidly developing clinical signs of focal or global disturbance of cerebral function with no apparent 
cause other than a vascular origin. History of stroke at baseline was assessed during the baseline 
interview and verified in medical records. Strokes are further classified as cerebral infarction or 
intracerebral hemorrhage based on neuroimaging reports. If neuroimaging is lacking, a stroke is 
classified as unspecified. Subarachnoid hemorrhages were excluded. Ischemic strokes are subtyped 
into large-vessel disease, small vessel disease, or cardio-embolic based on all available clinical and 
imaging data. If insufficient information is present to reliably subtype into one of three categories, the 
ischemic stroke is classified as unspecified ischemic stroke. For the current study, too few cases of 
ischemic stroke subtypes were present to reliably perform statistical analyses. 
Participants were followed from baseline to stroke, death, last health status update when they were 
known to be stroke-free, or January 1, 2005, whichever came first. Follow-up was complete up to 
January 1, 2005, for 99.1% of potential person-years.  
Wellcome Trust Case-Control Consortium 2 (WTCCC2)  
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study. Stroke cases 
included samples recruited by investigators at St. George's University London (SGUL) and University 
of Oxford in the UK and the Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians-
University, Munich.  
The SGUL collection comprised 1224 ischemic stroke samples from a hospital based setting. All cases 
were of self reported Caucasian ancestry. Ischemic stroke subtypes were determined according to 
TOAST criteria based on relevant clinical imaging and available information on cardiovascular risk 
factors. The University of Oxford collection comprised 896 ischemic stroke cases, consecutively 
collected as part of the Oxford vascular study (OXVASC). Cases were of self reported Caucasian 
ancestry, and ischemic stroke subtypes were determined according to TOAST criteria based on relevant 
clinical imaging. The University of Edinburgh collection comprised 727 ischaemic stroke cass, 
consecutively collected as part of the Edinburgh Stroke Study. Cases were of self-reported Caucasian 
ancestry, with ischaemic stroke subtypes determined according to TOAST criteria based on relevant 
clinical and imaging data. The Munich samples included 1383 ischemic stroke cases. Cases were 
consecutive European Caucasians recruited from a single dedicated Stroke Unit at the Department of 
Neurology, Klinikum Großhadern, Ludwig-Maximilians-University, Munich. Ischemic stroke subtypes 
were determined according to TOAST criteria based on relevant clinical and imaging data.  
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 1958 Birth 
Cohort. This is a prospectively collected cohort of individuals born in 1958 
(http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development study 
(http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). Data from this cohort are available as a 
common control set for a number of genetic and epidemiological studies. For the German samples 
controls were Caucasians of German origin participating into the population KORAgen study 
(www.gsf.de/kora/en/english.html). This survey represents a gender- and age stratified random sample 
of all German residents of the Augsburg area and consists of individuals 25 to 74 years of age, with 
about 300 subjects for each 10-year increment. All controls were free of a history of stroke or transient 
ischemic attack.  
Genome-wide genotyping and quality control in discovery studies 
The Atherosclerosis Risk in Communities Study (ARIC) 
Methods of genotyping, quality-control assessment and filtering, and genotype imputation have been 
described in 3. Briefly, genotyping was performed with the GeneChip SNP Array 6.0 (Affymetrix). 
Subject specific quality control filters included filters for call rate, heterozygosity, sex mismatch. SNP 
specific quality control filters included filters for call rate, minor allele frequency (MAF), Hardy-
Weinberg equilibrium (HWE), and differential missingness by outcome or genotype. The set of 
genotyped input SNPs used for imputation was selected based on high quality GWA data. We used a 
callrate >95%, HWE p-value>5x10-6; MAF>0.01. A total of 704,588 SNPs passing QC criteria were 
used for imputation, which was performed with the MaCH v1.0.16 software.!
Australian Stroke Genetics Collaborative (ASGC) 
The ASGC sample was genotyped using the Illumina HumanHap610-Quad array. Quality control 
excluded SNPs with genotype call rate <0.95, deviation from Hardy-Weinberg equilibrium (P<1!10-6) 
or minor allele frequency <0.01. At the sample level, quality control excluded individuals with: (i) 
genotype call rate <95% (n=4); ii) genome-wide heterozygosity < 23.3% or > 27.2% (n=9); iii) 
inadequate clinical data or inconsistent clinical and genotypic gender (n=45) and; iv) an inferred first- 
or second-degree relative in the sample based on pair-wise allele sharing estimates (estimated genome 
proportion shared identical by descent (IBD): pi-hat >0.1875 : n=37). Following these exclusions, 
Eigenstrat principal components analysis (PCA) was performed, incorporating genotype data from 
Phase 3 HapMap populations (CEU, CHB, JPT, TSI, YRI). In eigenvector plots, the majority of ASGC 
samples clustered closely with European (CEU and TSI) reference populations. Eighteen samples (16 
cases and 2 controls) showed prominent evidence of Asian ancestry and were removed. Principal 
component and IBD analyses were performed using a pruned subset of quasi-independent SNPs 
(~130,000 SNPs) to avoid confounding by linkage disequilibrium (LD). Following quality control, 
1162 cases and 1244 controls were available for association analyses at 551,514 SNPs.  
Genotype imputation in the filtered sample was performed using MACH v1.0.16 
(http://www.sph.umich.edu/csg/yli/mach/index.html), based on HapMap Phase 2 (release #24) phased 
haplotypes for European-ancestry (CEU) samples. Subsequent quality control excluded imputed SNPs 
with MAF <0.01 or ratio of observed dosage variance to expected binomial variance of r2 <0.3. 
Bio-Repository of DNA in Stroke (BRAINS) 
The BRAINS sample was genotyped using the Illumina HumanHap610-Quad array. Quality control 
excluded SNPs not genotyped on all case and control collections and SNPs with genotype call rate 
<0.95, deviation from Hardy-Weinberg equilibrium (P<1!10-6) or minor allele frequency <0.01. 
Individual samples were excluded due to low call rates (<95%), gender discrepancy, unexpected 
relatedness or evidence of non-European ancestry.   
Genotype imputation was performed using MACH v1.0.16 
(http://www.sph.umich.edu/csg/yli/mach/index.html), based on HapMap Phase 2 (release #22) phased 
haplotypes for European-ancestry (CEU) samples. Quality control removed imputed SNPs with MAF 
<0.01 or ratio of observed dosage variance to expected binomial variance of r2 <0.3.  Analyses were 
performed using PLINK v 1.6 (http://pngu.mgh.harvard.edu/~purcell/plink/). 
Cardiovascular Health Study  (CHS) 
In 2007-2008, genotyping was performed at the General Clinical ResearchCenter's 
Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV Duo® BeadChip 
system on the first 2,427 of 3,980 CHS participants who were free of CVD at baseline. The 1,908 
persons excluded for prevalent CVD had prevalent coronary heart disease (n=1195), congestive heart 
failure (n=86), peripheral vascular disease (n=93), valvular heart disease (n=20), stroke (n=166) or 
transient ischemic attack (n=56). Some persons had more than one reason to be excluded and for these 
individuals only the initial exclusionary event is listed. The 2,427 participants who had been genotyped 
by July 2008(time of the meta-analysis) were a stratified probability sample that included all cases of 
myocardial infarction (MI), stroke, atrial fibrillation, dementia, and heart failure, and a selection of 
controls sampled based on the age-, and sex distribution of MI cases. Sampling weights were used in 
the analysis to account for the study design and to weight back to the underlying cohort selected for 
genotyping (N=3,980). Because the other cohorts were predominantly white, the African American 
participants were excluded from the initial meta-analysis to limit the potential for false positive 
associations due to population stratification. At the time of the meta-analysis, genotyping had been 
attempted in 2,101 white participants, and was successful in 2,022 persons; the latter constitute the 
CHS sample for this study. QC criteria used to define successful genotyping are listed elsewhere, 35 
persons were excluded for a subject specific call rate !95%.  
The set of genotyped input SNPs used for imputation was selected based on the highest quality GWA 
data. We used a callrate >95%; a minor allele frequency >0.01; a Hardy- Weinberg p>1x10-9; and a 
test of differential missingness by the “mishap” test in PLINK p>1x10-9. We used BIM-BAM to 
impute to the plus strand of NCBI build 35. For each imputed SNP a reliability of imputation was 
estimated (as the ratio of the empirically observed dosage variance to the expected binomial dosage 
variance: O/E ratio).  
deCODE Genetics 
The Icelandic chip-genotyped samples were assayed with the Illumina Human Hap300, Hap CNV370, 
Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics. SNPs were excluded if (i) yield was 
lower than 95%, (ii) minor allele frequency was less than 1% in the population, (iii) significant 
deviation from Hardy-Weinberg equilibrium was observed in the controls (P < 0.001), (iv) an excessive 
inheritance error rate (over 0.001) was produced or (v) there was a substantial difference in allele 
frequency between chip types (from just a single chip if that resolved all differences, but from all chips, 
otherwise). All samples with a call rate below 97% were excluded from the analysis. Imputation was 
performed using IMPUTE. 
Framingham Heart Study (FHS) 
FHS participants had DNA extracted and provided consent for genotyping in the 1990s. All available 
eligible participants were genotyped at Affymetrix (Santa Clara, CA) through an NHLBI funded SNP-
Health Association Resource (SHARe) project using the Affymetrix GeneChip® Human Mapping 
500K Array Set and 50K Human Gene Focused Panel.® In 272 persons (31 with stroke), small amounts 
of DNA were extracted from stored whole blood and required whole genome amplification prior to 
genotyping. Cell lines were available for most of the remaining participants. Genotyping was attempted 
in 5293 participants, and 4,519 persons met QC criteria. Failures (call rate <97%, extreme 
heterozygosity or high Mendelian error rate) were largely restricted to persons with whole-genome 
amplified DNA and DNA extracted from stored serum samples. We also excluded 156 participants 
who were less than 45 years old at the time of the DNA draw, 135 persons with prevalent stroke and 97 
persons who did not have stroke surveillance on follow-up after genotyping; the remaining 4,131 
subjects constitute the FHS sample for this study.  
The set of genotyped input SNPs used for imputation was selected based on the highest quality GWA 
data. We used a callrat; >97%; a minor allele frequency >0.01; a Hardy- Weinberg p>1x10-6; and a 
test of differential missingness by the “mishap” test in PLINK p>1x10-9 in each study. We used the 
Markov Chain Haplotyping (MaCH) package (http://www.sph.umich.edu/csg/abecasis/MACH) version 
1.0.15 software to  impute to plus strand of NCBI build 36, HapMap release #22. For each imputed 
SNP a reliability of imputation was estimated (as the ratio of the empirically observed dosage variance 
to the expected binomial dosage variance: O/E ratio). For the primary meta-analysis using inverse-
variance weighting less weight is given to imputed SNPs with low observed dosage variance (resulting 
in higher variance of the estimate). For the secondary meta- analysis using the inverse square root (N) 
weighting the ratio was used to compute an effective sample size. 
The Genetics of Early Onset Stroke (GEOS) Study, Baltimore, USA 
Samples were genotyped at the Johns Hopkins Center for Inherited Disease Research (CIDR), and 
genotyping was performed using the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San 
Diego, CA, USA).  Case and control samples were balanced across the plates. Allele cluster definitions 
for each SNP were determined using Illumina BeadStudio Genotyping Module version 3.3.7, Gentrain 
version 1.0 and the combined intensity data from all released samples. Genotypes were not called if the 
quality threshold (Gencall score) was below 0.15.    
All samples had a genotype call rate > 98%. Genotyping concordance rate was 99.996% based on study 
duplicates.  Samples were excluded due to unexpected duplicates, gender discrepancy, unexpected 
relatedness or evidence of non-European ancestry based on principal components analysis.  Individual 
SNPs were excluded from analysis if they had excessive deviation from Hardy-Weinberg Equilibrium 
(HWE) proportions (P < 1.0x10-6), genotype call rates <97.5% or minor allele frequency < 1%.  
Departure from HWE was assessed by chi-square test among controls only. 
Heart Protection Study (HPS) 
DNA was extracted from stored white cells and genotyping was carried out at the Centre National de 
Génotypage in Evry, France. Genotypes were measured using the Illumina 610K Quad panel, called 
using Illumina BeadStudio software, and imputed with reference to HapMap2 CEU release 22 (build 
36) using MACH. Single nucleotide polymorphisms with <97.5% call rate, significant deviation from 
Hardy-Weinberg equilibrium (p<1x10-6) or low minor allele frequency (<0.01) were excluded. 
Genotype data were available for 578 stroke cases and 468 controls after quality control exclusions for 
discrepant sex, repeated samples and non-European ancestry. Statistical analyses were performed using 
MACH2QTL.  
The Heart and Vascular Health Study (HVH) 
Genotyping was performed at the General Clinical Research Center's Phenotyping/Genotyping 
Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system. Genotypes were called 
using the Illumina BeadStudio software. Samples were excluded from analysis for sex mismatch or call 
rate < 95%. The following exclusions were applied to identify a final set of 301,321 autosomal SNPs: 
call rate < 97%, HWE P < 10-5, > 2 duplicate errors or Mendelian inconsistencies (for reference CEPH 
trios), heterozygote frequency = 0, SNP not found in HapMap, inconsistencies across genotyping 
batches.  Imputation was performed using BIMBAM with reference to HapMap CEU using release 22, 
build 36 using one round of imputations and the default expectation-maximization warm-ups and runs.   
Logistic regression was used to investigate the association of each SNP with the risk of stroke and MI, 
adjusting for the matching factors of age, sex, hypertension status and index year. We used linear 
additive models with robust standard errors and estimated risk for each additional copy of the variant 
allele, using R. SNPs were excluded from analysis for variance on the allele dosage !0.01.  
The Ischemic Stroke Genetics Study (ISGS)/ Siblings With Ischemic Stroke Study (SWISS) 
Both the ISGS/SWISS cases were genotyped using the Illumina 610 or 660 genotyping arrays, while 
control series used in the ISGS/SWISS dataset were genotyped using the Illumina HumanHap 550Kv1 
or 550Kv3 genotyping arrays.  Genotypes were called using Illumina GenomeStudio software, with all 
alleles called on the forward strands. All A/T and G/C SNPs were removed prior to merging case and 
control sample sets.  Also SNPs with discordant minor alleles on the same strand across microarrays 
were removed prior to merging datasets. Preliminary exclusion criteria per sample included genome-
wide SNP call rates <95% and discordance between self-reported gender and sex determined from X 
chromosome heterozygosity. SNPs were excluded from the merged case-control series if genotyping 
success rate <95%, minor allele frequency (MAF) <0.01, Hardy-Weinberg equilibrium (HWE) 
P<1E"4 in controls and P<1E"7 in cases, nonrandom missingness per haplotype P<1E"5 and 
missingness in cases compared to controls (from chi-squared test) P<1E"5. 
ISGS/SWISS cases and controls were merged with a subset of samples from HapMap 3 (ASW, CEU, 
CHB, JPT, TSI and YRI populations) and underwent multidimensional scaling analyses to verify 
European ancestry with principal component vector 1 (PC1) and 2 (PC2) values greater than 3 standard 
deviations from the combined CEU/TSI means for each vector were excluded as outliers. Samples 
were excluded if they shared greater than a 0.125 proportion of alleles (pi_hat >0.125). Basic quality 
control of genotyped SNP data was carried out using PLINKv1.07.  The SNPs passing quality control 
for the ISGS/SWISS were imputed using a two-stage procedure implemented in Markov Chain based 
haplotyper (MACH; version 1.0.16) under default settings. For this study, the August 2010 release of 
the 1000 Genomes European ancestry haplotypes was utilized as a reference for SNP imputation. 
The MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS) 
Cases and controls were genotyped using the Affy 6.0 array. Quality control procedures excluded SNPs 
with >5% missingness, minor allele frequency <0.01, or Hardy-Weinberg p-value < 10-7. Individual 
samples were excluded if they exhibited genotype missingness >5%, cryptic relatedness (one of each 
pair demonstrating pi_hat [estimated proportion of genome shared identical by descent] > 0.15 was 
removed), or non-European ancestry based on multi-dimensional scaling analysis using HapMap Phase 
3 populations. Analyses were performed using PLINK v 1.6 
(http://pngu.mgh.harvard.edu/~purcell/plink/). Imputation was performed using MACH v 1.0.16 
(http://www.sph.umich.edu/csg/yli/mach/index.html) and the HapMap 3 CEU+TSI training set.  
Milano 
Italian cases were genotyped using Illumina Human610-Quad v1_B or Human660W-Quad v1_A chips. 
Italian controls were genotyped with the Illumina HumanHap610-Quad chip. PCA with HapMap 3 on 
the Italian cases showed that Italian PROCARDIS controls had similar ancestry to the cases. All 
samples had a genotype call rate > 95%. Samples were excluded due to unexpected duplicates or 
evidence of non-European ancestry based on principal components analysis. Quality control procedures 
excluded SNPs with MAF <0.01 or Hardy-Weinberg P-value <5!10-6 in either the case or control 
collections. 
Rotterdam 
All participants had DNA extracted at baseline in 1990-1993. In 2007-2008, genotyping was attempted 
in participants with high-quality extracted DNA at baseline. Genotyping was done at the Human 
Genotyping Facility, Genetic Laboratory Department of Internal Medicine, Erasmus MC, Rotterdam, 
The Netherlands. Genotyping was carried out using the Illumina HumanHap550 Duo BeadChip® 
according to the manufacturer’s protocols. Participant-specific quality-control included filters for call 
rate, heterozygosity, and number of Mendelian errors per individual. SNP-specific quality control 
included filters for call rate, minor allele frequency, Hardy-Weinberg equilibrium, and differential 
missingness by outcome or genotypes (mishap test in PLINK). Data were screened for latent 
substructure, including cryptic relatedness, using IBD matrix. 
The set of genotyped input SNPs used for imputation was selected based on their highest quality GWA 
data. We used a call rate >98%, a minor allele frequency >0.01, a Hardy-Weinberg p>1x10-6 
Rotterdam, and a test of differential missingness by the “mishap” test in PLINK p>1x10-9 to selected 
SNPs used for imputation. We used the Markov Chain Haplotyping (MaCH) package 
(http://www.sph.umich.edu/csg/abecasis/MACH) to impute to the plus strand of NCBI build 36, 
HapMap release #22. Imputation of genotypes provides a dosage value for every SNP between 0 and 2 
indicating the expected value of a SNP being homozygous for the reference allele. For each imputed 
SNP an assessment of the informativeness of the imputation was estimated (as the ratio of the 
empirically observed dosage variance to the expected binomial dosage variance, O/E ratio). 
Wellcome Trust Case-Control Consortium 2 (WTCCC2)  
All WTCCC2 cases were genotyped as part of the WTCCC2 Ischemic Stroke study using the Illumina 
Human660W-Quad array. British controls were genotyped using the Illumina Human1.2M-Duo. 
German controls were genotyped on the Illumina Human 550k platform. Quality control procedures in 
the WTCCC2 excluded SNPs not genotyped on all case and control collections and SNPs with Fisher 
information measure <0.98, genotype call rate <0.95, MAF <0.01 or Hardy-Weinberg P-value <1!10-
20 in either the case or control collections. Samples were excluded if identified as outliers on call rate, 
heterozygosity, ancestry and average probe intensity based on a Bayesian clustering algorithm. 
Samples were also removed if they exhibited discrepancies between inferred and recorded gender or 
cryptic relatedness with other WTCCC2 samples (pairwise identity-by-descent >0.05). Autosomal 
genotype imputation was performed using MACH based on HapMap Phase 2 European (CEU) 
reference data. 
 
Supplementary Table 6: Proportion of stroke cases with investigations performed in the replication cohorts.  
 
Cohort 
Number of 
Cases 
Brain imaging with CT 
or MRI (%) MRI (%) ECG (%) Echocardiographic Imaging (%) Extracranial cerebral artery imaging (%) 
Barcelona 439 100 18 100 70 100 
BSS 225 100 - 100 100 100 
Copenhagen 730 - - - - - 
Go-Darts*** 737 - - - - - 
ESS 276 100 21 99 33 95 
Glasgow 675 100 18 100 35 100 
Graz 657 100 41.9 99.7 39.2 99.7 
Interstroke* 1126 99.3 14.2 98.8 37.6 37.5 
Krakow 1235 100 8.0 100 54.8 85.3 
Leuven* 531 100 89 100 95 99.6 
Lund 424 100 - 100 17.2 - 
Munster 1232 97.2 45.4 - 77.4 97.7 
Portugal 539 100 25 97 - - 
Pakistan (RACE) 1322 100 55 100 100 91 
SMART 623 90.7 - -** - 100 
Swedish (Karolinska) 876 100 16 100 38 - 
VISP* 1726 99.9 47.0 99.9 - - 
WHI 302 - - - - - 
BSS=Belgium Stroke Study. ESS=Edinburgh Stroke Study. Go-Darts=4G5enetics of Diabetes Audit and Research in Tayside Study. RACE=Risk Assessment of 
Cerebrovascular Events Study, Pakistan. SMART=Second Manifestations of ARTerial disease. VISP=The Vitamin Intervention for Stroke Prevention Trial. WHI=The 
Women’s Health Initiative. CT=Computed Tomography. MRI=Magnetic Resonance Imaging. ECG=Electrocardiogram. “-“=data not available, not recorded or performed 
only as clinically indicated. Extracranial cerebral arterial imaging includes carotid and vertebral artery ultrasound, or computed tomographic angiography, or magnetic 
resonance angiography. *=values given are for individuals prior to genotypic QC steps. **=We have no exact numbers of patients with ecg, probably 100% (not registered), 
but none of the included patients had atrial fibrillation; ***=Cases were identified through hospital admissions codes so while they may have had investigations performed 
we do not have that information for all cases.  
 Supplementary Table 7: Replication Cohort Characteristics 
 Sample size Age (mean ± SD) Male Gender (%) 
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Imaging (%) 
 
Sample 
IS
 
SV
D
 
C
E
 
L
V
D
 
co
nt
ro
ls
 
IS
 
SV
D
 
C
E
 
L
V
D
 
co
nt
ro
ls
 
IS
 
SV
D
 
C
E
 
L
V
D
 
co
nt
ro
ls
 
Barcelona 439 150 179 110 404 72.0 ± 12.8 70.1± 
12.2 
75.4 ± 
13.6 
69.9 ± 11.3 71.5 ± 7.2 53.4 59.6 39.5 66.4 43.8 100 
BSS 225 90 11 93 312 52.8 ± 5.4 53.5 ± 5.0 49.9 ± 
8.5 
52.4 ± 5.0 69.8± 8.8 64.0 66.0 36.4 64.5 64.5 99.6 
Copenhagen 730 - - - 1545 63.1 ± 9.1 - - - 64.8 ± 10.7 45.5 - - - 62.6 - 
ESS 276 69 40 20 987* 71.4 ± 11.4 67.4 ± 
11.8 
74.9 ± 
13.1 
75.1 ± 7.1 69.6 ± 
0.83* 
52.5 59.4 55.0 55.0 51.2* 100 
Glasgow 675 150 125 91 987* 69.9 ± 12.2 69 ± 13.7 71.1± 10.3 68.5 ± 11.7 
69.6 ± 
0.83* 
52.5 58.6 49.9 50 51.2* 100 
Go-Darts 737 - 130 259 8442 69.0± 9.8 - 75.7 ± 8.6 70.9 ± 8.9 65.0 ± 11.4 59.2 - 61.0 61.6 51.2 - 
Graz 657 207 116 108 848 68.9 ± 14.5 
69.2 ± 
15.6 
72.7 ± 
10.0 66.9 ± 13.7 65.2 ± 8.1 57.5 57.0 59.5 54.6 43.2 100 
Interstroke* 872 238 143 198 926 62.6 ± 14.4 61.1± 
13.5 
67.9± 
16.2 
61.6± 14.6 61.2± 13.5 56.1 57.1 58.8 49.5 59.6 99.3 
Krakow 1235 171 377 152 584 67.4±14.2 63.6 ± 
12.3 
70.1 ± 
13.5 
66.7 ± 11.2 58.4 ± 17.8 49.3 54.5 44.0 62.8 47.5 100 
Leuven* 531 63 195 83 445 68.9 ± 13.5 
 
 
 
65.6 ± 
14.6 
70.5 ± 
13.0 
 
 
 
 
68.7 ± 10.6 57.6 ± 14.2 60 62 61 67 43 100 
Lund 424 94 140 21 466 74.4 ± 11.3 70.6 ± 
12.1 
78.1± 9.9 70.7 ± 9.3 73.4 ± 11.2 56.4 60.6 51.4 71.4 58.2 100 
Munster 1232 224 478 528 1053 69.3 ± 14.5 68.4 ± 
13.0 
71.8± 
14.5 
67.5 ± 14.8 53.0±13.6 53.2 52.2 47.5 58.7 46.7 97.2 
Portugal 539 - - - 507 52.5 ± 9.3 - - - 62.9 ± 6.9 63.1 - - - 46.2 100 
RACE 
(Pakistan) 
1322 189 225 195 1143 52.9 ± 10.6 53.8 ± 9.4 52.9 ± 
11.2 
54.5 ± 9.2 51.9 ± 7.9 52.4 52.4 62.2 50.8 53.4 100 
SMART 623 195 30 368 6712 60.6 ± 10.9 58.8± 
11.5 
63.2± 
10.6 
61.7± 10.3 55.7± 12.5 68.9 70.8 60.0 68.5 68.2 90.7 
BSS=Belgium Stroke Study. ESS=Edinburgh Stroke Study. Go-Darts=Genetics of Diabetes Audit and Research in Tayside Study. RACE=Risk Assessment of 
Cerebrovascular Events Study, Pakistan. SMART=Second Manifestations of ARTerial disease. VISP=The Vitamin Intervention for Stroke Prevention Trial. WHI=The 
Women’s Health Initiative. IS=Ischaemic Stroke. SVD=small vessel disease. LVD=large vessel disease. CE=cardioembolic stroke. “-“=information not available or not 
relevant. *=values given are for individuals prior to genotypic QC steps. 
Swedish 
(Karolinska) 
876 75 157 177 742 69.0 ± 11.2 65.7 ± 
10.1 
72.4 ± 
10.8 
69.7 ± 9.2 43.1 ± 12.3 56.9 60.0 54.0 67.8 59.8 100 
VISP 1726* - - - 1047 68.0 ± 10.7 - - - - 65.0 - - - 59.4 99.9 
WHI 302 78 42 31 2099 - - - - - 0 0 0 0 0 - 
Ascertainment and clinical assessment of participants in Replication studies 
Barcelona 
Patients with ischemic stroke were recruited consecutively at the stroke unit of Vall d’Hebron Hospital, 
Barcelona, Spain. Only patients admitted at the stroke unit with stroke resulting from large and small 
vessel disease as well as CE origin were included in the genetic study. All patients underwent brain 
imaging by CT scan, and some had additional MRI performed. ECG and extracranial and intracranial 
arterial ultrasound examination were performed in all patients, and Holter monitoring and 
echocardiography were performed on patients with clinical suspicion of a CE source or undetermined 
origin. Control participants were selected from relatives of patients (wife or husband, without any 
consanguinity among cases and controls) and healthy volunteers visiting the same hospital for routine 
testing. They were _65 years of age and classified as free of neurovascular and cardiovascular history 
and familial history of stroke by direct interview before recruitment. 
The Belgian Stroke Study (BSS) 
BSS is a case-control study. 237 stroke patients were classified according to the TOAST classification, 
all occurring between 45 and 60 years of age. The patients were selected from the databases of 7 Stroke 
Units in Belgium. All patients were of central European origin (>90 % were Belgians). Cardiovascular 
risk factors were recorded. The control group was composed of 326 gender- and ethnicity-matched 
healthy volunteers without a story of stroke and living in the same area. The study protocol was 
approved by the ethical committees of all participating hospitals. Written informed consent was 
obtained from all patients before study entry. 
Copenhagen General Population Study and Copenhagen Carotid Stroke Study 
This cohort included 750 patients from the greater Copenhagen area referred for carotid ultrasound at 
Copenhagen University Hospital, during the period 1991 through 2002, for outpatient ultrasonography 
of the carotid artery. Experienced neurologists and vascular surgeons diagnosed ischemic 
cerebrovascular disease on the basis of ischemic stroke (n=464) or transient ischemic attack or 
amarousis fugax (n=266), together with at least 50% stenosis of a carotid artery.22 Hemorrhage was 
excluded on computed tomography. The 1545 healthy controls were from the Copenhagen General 
Population Study.23 
Edinburgh Stroke Study (ESS) 
Consecutive consenting patients with stroke who were admitted to or seen as outpatients at the Western 
General Hospital, Edinburgh between 2002 and 2005 were prospectively recruited. Cases in this study 
were those with a clinically evident stroke, demonstrated by brain imaging (CT or MRI) to be 
ischaemic. An experienced stroke physician assessed each patient as soon as possible after the stroke, 
prospectively recording demographic and clinical details, including vascular risk factors and results of 
brain imaging and other investigations. 726 cases were included in the WTCCC2 ischaemic stroke 
case-control study and contribute to the discovery component of this study, while 276 cases were 
included as a replication study. Controls for the Edinburgh replication study are 987 stroke-free 
subjects drawn from The Lothian Birth Cohort 1936,24 currently living in the Lothian area of Scotland 
(mainly in Edinburgh). 
Glasgow 
Patients with ischemic stroke attending the cerebrovascular service of the Western Infirmary, Glasgow, 
were recruited between 1990 and 2004 as part of an ongoing study of genetic and circulating 
biomarkers in stroke. All patients underwent brain imaging and extracranial carotid ultrasound in 
accordance with a standard clinical protocol. The study was approved by the West Ethics Committee.  
Genetics of Diabetes Audit and Research in Tayside Study (Go-Darts) 
The recruitment of the Diabetes Audit and Research in Tayside Study (DARTS) and the subsequent 
Genetics of DART study (Go-DARTS) are described in detail elsewhere.25,26 Briefly, the Genetics of 
Diabetes Audit and Research in Tayside Study (Go-DARTS) comprises 17,602 participants enrolled 
between December 1998 and May 2009 in which there are approximately equal numbers of 
participants with and without a diagnosis of type 2 diabetes mellitus. Relevant clinical data for all Go-
DARTS participants are drawn from electronic records of hospital admissions (Scottish Morbidity 
Register, SMR), deaths (General Registry Office, GRO), biochemical tests and dispensed drug 
prescriptions, available for the Tayside region.   Approval for the current analysis was given by the Go-
DARTS access committee, under standard operating procedures approved by Tayside Research Ethics 
Committee.  Ischaemic stroke events were identified from hospital admissions and death records using 
the following ICD9 433, 434 and ICD10 I63, I64 and G459.  Controls were defined as individuals free 
of any haemorrhagic and, or ischaemic stroke and, or coronary artery disease and, or lower extremity 
arterial disease.   
Graz Stroke Study 
Between 2002 and 2007 white patients with ischemic strokes admitted to the stroke unit of the Medical 
University Graz Department of Neurology were included. All patients underwent either CT or MRI of 
the brain and a standardized protocol including a laboratory examination and carotid ultrasound or 
magnetic resonance angiography and ECG. More extensive cardiac examination, including 
transesophageal echocardiography or transthoracic echocardiography and Holter, was done in subjects 
with suspected cardiac embolism. A total of 657 stroke patients were included in the study. The Stroke 
subtype was assessed according to modified Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
criteria. Subtyping was done by trained stroke neurologists. 
Controls were participants of the Austrian Stroke Prevention Study27 and came from the same 
catchment area. All control subjects were recruited between 1991 and 2000 and were free of stroke and 
dementia. They underwent full risk factor assessment, brain MRI, Duplex scanning of the carotid 
arteries, ECG, and transthoracic echocardiography. 
Interstroke 
INTERSTROKE is an international, multicenter case-control study. Cases are patients with a first 
stroke within 72 h of hospital presentation in whom CT or MRI is performed. Proxy respondents are 
used for cases unable to communicate. Etiological and topographical stroke subtype is documented for 
all cases. Controls are hospital- and community-based, matched for gender, ethnicity and age (±5 
years). A questionnaire (cases and controls) is used to acquire information on known and proposed risk 
factors for stroke. Cardiovascular (e.g. blood pressure) and anthropometric (e.g. waist-to-hip ratio) 
measurements are obtained at the time of interview. Nonfasting blood samples and random urine 
samples are obtained from cases and controls. 
Leuven 
Cerebral ischemia, defined as a clinical stroke with imaging confirmation or a TIA with a new 
ischemic lesion on diffusion weighted MRI, who were admitted to the Stroke Unit of the University 
Hospitals in Leuven. All patients underwent brain imaging (MRI in 91% of patients, CT in the 
remainder) and a standardized protocol including carotid ultrasound or CT angiography and cardiac 
examination (echocardiography and Holter monitoring) in all patients. Control individuals were 
selected from the same population and were either spouses of patients with multiple sclerosis, 
amyotrophic lateral sclerosis or stroke or healthy community dwelling subjects partially from the 
Leuven University Gerontology Database.  Controls either confirmed they never had a stroke or TIA or 
responded negative to any item of the Verification of Stroke Free Status questionnaire.  
Lund Stroke Register, Sweden 
Lund Stroke Register (LSR) since 2001 continuously enrols patients aged 18 and older with first-ever 
stroke, living in the primary uptake area of Skåne University Hospital, Lund. The study is mainly 
hospital-based but has a good coverage of the whole geographical population.28 All included patients 
are examined with CT/MR or autopsy of the brain. When clinically indicated, the patients are 
examined with ultrasound imaging of carotid arteries, echocardiography, and angiography. In this 
study, first-ever ischemic stroke patients from LSR between 2001 and 2002 were included as well as 
control subjects from the same geographical uptake area. All patients were assessed by a neurologically 
trained physician regarding stroke type. The control subjects were individuals without stroke, randomly 
selected from the official Swedish Population Register and matched for age and gender to the stroke 
patients. Presence of hypertension, diabetes mellitus, heart disease, smoking and hypercholesterolemia 
was registered for patients and control subjects. Informed consent was obtained from all individuals or 
when they were not able to respond from their next-of-kin. The study was approved by the Ethics 
Committee of Lund University.  
Münster (Westphalian Stroke Cases and Controls from the Dortmund Health Study, Germany) 
In Westphalia patients were recruited through hospitals participating in the regional Westphalian 
Stroke Register,29 located in the west of the country. For this analysis ischemic stroke patients recruited 
during the period 2000-2005 were included. The register’s standardized patient documentation form 
included major stroke type and severity, comorbidities, diagnostic and therapeutic details of the 
treatment process.  Ischemic stroke was further subtyped according to the TOAST classification by the 
documenting physician. Patients who had experienced a transient ischaemic attack or a haemorrhagic 
stroke were excluded from this analysis. 
Controls were drawn from the population based, prospective Dortmund Health Study (DHS),30 
conducted in the same region. Aim of the study was the assessment of the prevalence and incidence of 
different headache types as well as other chronic health conditions and to analyse their consequences 
on daily activities of those affected. Participants were randomly drawn from the registration office in 
the city of Dortmund, within the age range 25 to 74 years and stratified by gender. They participated in 
a face to face health interview and several physical examinations in the baseline assessment in 2003/4. 
Cases with a history of stroke (n=28) were excluded from this analysis.  
Both studies were approved by the ethics committee of the University of Muenster.  All participants 
gave their informed consent. 
Poland:Krakow 
Patients were recruited in the stroke unit of the Jagiellonian University in Krakow, Poland (a single-
center study). All stroke patients and controls were !18 years of age and were white.  
All patients had clinically relevant diagnostic workup performed, including brain imaging with 
computed tomography (CT) (100%) and/or magnetic resonance imaging (MRI) (8%) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and vertebral 
arteries (85.2%), echocardiography (54.8%). MR-angiography, CT-angiography Holter monitoring, 
transesophageal echocardiography and blood tests for hypercoagulability  were performed were 
indicated. Patients were classified into etiologic subtypes according to the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST).   
The control group included unrelated subjects taken from the population of southern Poland. Control 
subjects had no apparent neurological disease based  on the findings in a structured questionnaire and a 
neurological examination.   
The study was approved by local research ethics committees and informed consent was obtained from 
all participants.  
Portugal 
The Portuguese stroke cases and controls used in this study were ascertained and collected as described 
previously.31 Briefly, unrelated patients with a clinical diagnosis of IS, who were under the age of 65 at 
stroke onset, were recruited through Neurology and Internal Medicine Departments throughout 
Portugal. All patients were seen, and all neuroradiology tests were reviewed by study neurologists. 
Trauma, tumors, infection, and other causes of neurological deficit were excluded. Since stroke is a 
late-onset disease, the control group was selected from a group of healthy volunteers with a higher 
mean age than the case group, thus minimizing the chances for mis-classification as “stroke-free”. 
Control individuals were verified to be free of stroke by direct interview before recruitment, but no 
brain imaging studies were performed. All participants were adults of Portuguese Caucasian origin. 
The research protocol was approved by the Ethics Committees of participating institutions, and all 
participants provided informed consent. 
Risk Assessment of Cerebrovascular Events (RACE) Study, Pakistan 
RACE is a retrospective case-control study designed to identify and evaluate genetic, lifestyle and 
biomarker determinants of stroke and its subtype in Pakistan. Samples were recruited from six hospital 
centres in Pakistan. Cases were eligible for inclusion in the study if they: (1) are aged at least 18 years; 
(2) presented with a sudden onset of neurological deficit affecting a vascular territory with sustained 
deficit at 24 hours verified by medical attention within 72 hours after onset (onset is defined by when 
the patient was last seen normal and not when found with deficit); (3) the diagnosis was supported by 
CT/MRI; and (4) presented with a Modified Rankin Score of < 2 prior to the stroke. TOAST and 
Oxfordshire classification systems were used to sub-phenotype all stroke cases. Control participants 
were individuals enrolled in the Pakistan Risk of Myocardial Infarction Study (PROMIS), a case-
control study of acute MI based in Pakistan. Controls in PROMIS were recruited following procedures 
and inclusion criteria as adopted for RACE cases. In order to minimize any potential selection biases, 
PROMIS controls selected for this stroke study were frequency matched to RACE cases based on age 
and gender and were recruited in the following order of priority: (1) non-blood related or blood related 
visitors of patients of the out-patient department; (2) non-blood related visitors of stroke patients; (3) 
patients of the out-patient department presenting with minor complaints. 
SMART-study, the Netherlands 
Patients aged 18 to 79 years, newly referred to the University Medical Center Utrecht, The 
Netherlands, with classical risk factors for arterial disease (hypertension, hyperlipidaemia, diabetes 
mellitus) or with symptomatic arterial disease (coronary heart disease, cerebrovascular disease, 
abdominal aortic aneurysm, or peripheral arterial obstructive disease) were included in the Second 
Manifestations of ARTerial disease (SMART) study. A detailed description of the study was published 
previously.32 Briefly, patients who gave their written informed consent underwent a standardised 
vascular screening programme, including a health questionnaire, laboratory assessment, and 
ultrasonography to investigate the prevalence of additional vascular diseases. The Ethics Committee of 
the hospital approved the study. For the current study we genotyped a total of 8246 consecutive 
patients. These patients were included between September 1996 and March 2010 and followed until 
March 2010 or death.33 We included all patients as cases who suffered from an ischaemic stroke at 
baseline of this study or during follow-up (n=623). The remaining patients were used as controls, with 
exclusion of 911 patients included with transient ischaemic attacks, retinal ischaemia or a stroke in 
their medical history (n=6712).    
South Stockholm Ischemic Stroke Study, Stockholm, Sweden 
Swedish patients with ischemic stroke attending the stroke unit or the stroke outpatient clinic at 
Karolinska University Hospital, Huddinge unit in Stockholm, Sweden, were recruited from 1996 to 
2002 as part of an ongoing genetic epidemiology study, the South Stockholm Ischemic Stroke Study 
(SSISS).  The Swedish controls used in this study are population-based controls recruited from the 
same region in central Sweden as the patients, representing the general population in this area. The 
individuals were either blood donors recruited at the Huddinge or Karolinska University Hospitals or 
healthy volunteers (recruited in 1990-1994) recruited by the Clinical Chemistry Department at the 
Karolinska University Hospital to represent a normal reference.  The study was approved by the 
Bioethics Committee of the Karolinska Institute. 
VISP 
The VISP trial (P.I. James Toole, MD, Wake Forest University School of Medicine (WFU); R01 
NS34447) was a multi-center, double-blind, randomized, controlled clinical trial that enrolled patients 
aged 35 or older with Homocysteine levels above the 25th percentile at screening and a non-disabling 
cerebral infarction (NDCI) within 120 days of randomization.34,35 NDCI was defined as an ischemic 
brain infarction not due to embolism from a cardiac source, characterized by the sudden onset of a 
neurological deficit.  The deficit must have persisted for at least 24 hours, or if not, an infarction in the 
part of the brain corresponding to the symptoms must have been demonstrated by CT or MRI imaging. 
The trial was designed to determine if daily intake of a multivitamin tablet with high dose folic acid, 
vitamin B6 and vitamin B12 reduced recurrent cerebral infarction (1° endpoint), and nonfatal 
myocardial infarction (MI) or mortality (2° endpoints). Subjects were randomly assigned to receive 
daily doses of the high-dose formulation (n=1,827), containing 25mg pyridoxine (B6), 0.4mg 
cobalamin (B12), and 2.5mg folic acid; or the low-dose formulation (n=1,853), containing 200µg 
pyridoxine, 6µg cobalamin and 20µg folic acid. Enrollment in VISP began in August 1997, and was 
completed in December 2001, with 3,680 participants enrolled, from 55 clinic sites across the US and 
Canada and one site in Scotland.  
WHI 
The WHI Hormone Trial HT (WHI-HT) consisted of two separate clinical trials in postmenopausal 
women ages 50 to 79 years at baseline—a trial of combined estrogen and progestin (Estrogen plus 
Progestin or E+P) in women who had an intact uterus at baseline (n=16,608) and a trial of estrogen 
(Estrogen Alone or E-Alone) in women who had a prior hysterectomy at baseline (n=10,739). 
Postmenopausal women who gave written informed consent were enrolled in the WHI at 40 clinical 
centers in the United States. Exclusions for safety reasons included prior diagnosis of breast cancer or 
other cancers within the past 10 years (except nonmelanoma skin cancer). Women with systolic blood 
pressure (SBP) of 200 mm Hg or higher or diastolic blood pressure (DBP) of 105 mm Hg or higher 
were advised to see their physician within a specified period depending on blood pressure level and 
were temporarily excluded from the clinical trials until their blood pressure was determined to be under 
control. Stroke diagnosis requiring and/or occurring during hospitalization was based on rapid onset of 
a neurological deficit attributable to an obstruction or rupture of an arterial vessel system. Hospitalized 
incident stroke events were identified by semiannual questionnaires and adjudicated following medical 
record review, which occurred both locally and centrally. Ischemic strokes were further classified by 
the central neurologist adjudicators according to the Oxfordshire and Trial of Org 10172 Acute Stroke 
Trial (TOAST) 
http://jama.jamanetwork.com.offcampus.lib.washington.edu/article.aspx?articleid=196626 - REF-
JOC30333-25 criteria to examine stroke subtypes. The TOAST classification focuses on the presumed 
underlying stroke mechanism and requires detailed investigations (such as brain computed 
tomography, magnetic resonance imaging, angiography, carotid ultrasound, and echocardiography). 
  
Genotyping and quality control in Replication studies 
 
European Replication (Barcelona, Belgium (BSS), Glasgow, Graz, Leuven, Lund, Krakow) 
Genotyping of European replication samples was carried out at the WTSI using Sequenom iPLEX 
Gold assays. Individual samples were excluded from analysis if they had call rates of <80% or if 
reported gender was discordant with gender-specific markers.  Pairs of samples showing concordance 
indicative of being duplicates were referred back to the originating cohort PI for confirmation of 
individual status, and where duplicates were identified one of each pair was removed. 
Genome-wide genotyping of Graz controls was performed at the Human Genotyping Facility, Genetic 
Laboratory Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. Genotyping 
platform was the Human610-Quad BeadChip (Illumina). Data were imputed to the 2.5 million 
autosomal single-nucleotide polymorphisms (SNPs) using HapMap CEU as the reference population. 
The set of genotyped input SNPs used for imputation was selected based on the highest quality GWA 
data. We used a callrate >95%, a minor allele frequency >0.01, a Hardy-Weinberg p>1x10-6 and a test 
of differential missingness by the “mishap” test in PLINK p>1x10-9. We used the Markov Chain 
Haplotyping (MaCH) package (http://www.sph.umich.edu/csg/abecasis/MACH) version 1.0.15 
software and imputed to plus strand of NCBI build 36, HapMap release #22 program. For each imputed 
SNP a reliability of imputation was estimated (as the ratio of the empirically observed dosage variance 
to the expected binomial dosage variance: O/E ratio).  
Controls for the Glasgow cohort were taken from the Edinburgh Stroke Study, described below. 
Copenhagen 
Samples were genotyped at Department of Clinical Biochemistry, Herlev Hospital, Copenhagen 
University Hospital (own lab) using TaqMan assays with call rates at 99% or above. Genotypes were in 
Hardy-Weinberg equilibrium. 
Edinburgh Stroke Study (ESS) 
Cases and controls were genotyped at the Wellcome Trust Clinical Research Facility genetics core 
laboratory at the Western General Hospital, Edinburgh. Cases for the replication study were genotyped 
on the ABI 7900HT platform, using Applied Biosystems Taqman 6.0. Controls were genotyped for 599
?011 common SNPs using the Illumina610-Quadv1 chip (Illumina, Inc., San Diego, CA, USA). 
Individuals were excluded based on unresolved gender discrepancy, relatedness, call rate (!0.95) and 
evidence of non-Caucasian descent. SNPs were included if they met the following conditions: call rate 
" 0.98, minor allele frequency " 0.01 and Hardy–Weinberg equilibrium test with p " 0.001.36 
Genetics of Diabetes Audit and Research in Tayside Study (Go-Darts) 
Individuals in the Go-DARTS population have been genotyped on both the Affymetrix 6.0 SNP 
genotyping array and the CardioMetabo Chip, genotyping data were combined across these two 
platforms to maximise the number of individuals available in each SNP association analysis.  4000 
individuals were genotyped on the Affymetrix 6.0 SNP genotyping array and these were imputed to 
HapMap2 and a British reference panel of 6000 individuals typed on the Illumina 1M dual.  An 
additional 7000 individuals were typed on the Cardio-Metabochip (Illumina).  QC was performed in 
each array population separately:  population outliers and one individual per related pair were removed, 
a minor allele frequency of greater than 0.01 was applied to both arrays, a call rate of greater than 95% 
was applied to each array, an HWE cut off of 1E-06 was applied to the Affymetrix 6.0 and 1E-04 was 
applied to the Cardio-Metabochip. Threshold called (0.9) imputed data were combined with directly 
typed data and the SNPs were tested for association with the stroke phenotypes.    
Interstroke 
Samples were genotyped at McMaster University using the Illumina Cardiometabochip (Illumina, San 
Diego, CA, USA).  Briefly, samples with a genotype call rate < 97% and SNPs a call rate <90% were 
excluded.  Samples were also excluded due to unexpected duplicates, gender discrepancy, unexpected 
relatedness or discrepancy between self-reported and genetic ancestry based on principal components 
analysis.  Individual SNPs were excluded from analysis if they had excessive deviation from Hardy-
Weinberg Equilibrium proportions (P < 1.0x10-6) in any ethnic group or minor allele frequency < 1% 
in all ethnic groups.  Departure from HWE was assessed by an exact method among controls only. 
Münster (Westphalian Stroke Cases and Controls from the Dortmund Health Study, Germany) 
Samples were genotyped at the Helmholtz Centre, Munich, using the iPLEX Gold Method 
(Sequenom). Average call rate of the variants measured was >96%.  Samples were excluded due to 
unexpected duplicates (9 samples) and gender discrepancy (60 samples). Individual SNPs were 
assessed for deviation from Hardy-Weinberg equilibrium (p<1e-5) and minor allele frequency 
(MAF<0.01). All of the variants tested passed these filters. 
Portugal 
T!"#$%&'()("*"#samples were genotyped in the Genomics Unit of the Instituto Gulbenkian de Ciência 
using Sequenom’s (San Diego, USA) iPlex assay#+%,,%-./)#01/(+12'(&"&3*#4&%'%2%,5#1/6#6"'"2'"6#./#1#7"8("/%0#91**:&&1;#<=#4,1'+%&0. Extensive quality control was performed using eight HapMap 
controls of diverse ethnic affiliation, sample duplication within and across plates, non-Mendelian 
inheritance check in three large pedigrees, Hardy–Weinberg equilibrium (HWE) in the control group (P 
> 0.05), and a minimum of 90% call rate. Genotype determinations were performed blinded to 
affection status. 
Risk Assessment of Cerebrovascular Events (RACE) Study, Pakistan 
All Samples were genotyped on the Illumina Human660W-Quad BeadChip but at two different 
centres. PROMIS controls were genotyped at the Wellcome Trust Sanger Institute (Sanger) and RACE 
cases were genotyped at the Center for Inherited Disease Research (CIDR). The raw scan data for cases 
and controls were clustered together at CIDR to obtain a combined set of genotypes using Illumina 
GenomeStudio 2010 v2, genotyping module 1.7.4 and Gentrain version 1.0. 
SNPs missing with more than 5% of samples were excluded, as were SNPs failing the Hardy-Weinberg 
equilibrium test at p < 1.0x10-7 and SNPs with minor allele frequency less than 1%.  All samples with 
less than 95% call rate were removed from the study. Gender checking was performed using PLINK, 
and samples with discrepancy between their reported sex and genetic sex were removed from the study. 
IBD sharing between samples were assessed to identify related samples, and one of each pair of the 
related samples was excluded from the study.  
SMART-study, the Netherlands 
Genotyping the 12 snps was performed by KBiosciences (Hoddesdon, United Kingdom). All 12 SNPs 
had a missingness <3.40% and a Hardy-Weinberg equilibrium p-value > 0.027. 
South Stockholm Ischemic Stroke Study, Stockholm, Sweden 
Samples were genotyped at deCODE genetics in Reykjavik, Iceland, using the Centaurus (Nanogen) 
platform (Kutyavin IV, Milesi D, Belousov Y et al. A novel endonuclease IV post-PCR genotyping 
system. Nucleic Acids Res. 2006;34:e128). The quality of each SNP assay was evaluated by comparing 
the genotyping of the CEU HapMap samples with the publicly available HapMap data.  All SNPs 
passed mismatch tests, linkage disequilibrium (LD) tests and were in Hardy-Weinberg equilibrium.   
VISP 
A subset of VISP participants gave consent and were included in the GWAS component of VISP, 
supported by the National Human Genome Research Institute (NHGRI), Grant U01 HG005160, as part 
of the Genomics and Randomized Trials Network (GARNET). Samples were genotyped at the Johns 
Hopkins Center for Inherited Disease Research (CIDR), and genotyping was performed using the 
Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Individuals were 
excluded if they were unexpected duplicates or had gender discrepancies. 
 All VISP participants are stroke cases, therefore we obtained GWAS data (dbGAP) for 1047 external 
controls from the High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes 
Investigation (Study Accession: phs000187.v1.p1).  These samples were also genotyped on the 
Illumina HumanOmni1-Quad. 
WHI 
WHI-GARNET participants were genotyped using the Ilumina Omni-quad chip at the Broad Institute, 
and imputation was performed into 1000 Genomes at the GARNET Coordinating Center (University of 
Washington) using BEAGLE. All SNPs passed QC and were in Hardy-Weinberg equilibrium. 
Association testing for typed or imputed SNPs was performed using PLINK. 
 
References 
1 The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and 
objectives. Am J Epidemiol 1989;129 :687–702. 
2 Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among 
middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. 
Stroke 1999;30 :736–743. 
3 The National Survey of Stroke. National Institute of Neurological and Communicative 
Disorders and Stroke. Stroke. 1981;12 :I1–91 
 4 Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based 
causative classification system for acute ischemic stroke. Ann Neurol. 2005;58 :688–697 
5 Yadav S, Schanz R, Maheshwari A, et al. Bio-Repository of DNA in stroke (BRAINS): a 
study protocol. BMC Med Genet 2011; 12: 34. 
6 Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and 
rationale. Ann Epidemiol 1991; 1: 263–76. 
7 Dawber TR, Kannel WB. The Framingham study. An epidemiological approach to coronary 
heart disease. Circulation 1966;34:553–555. 
8 Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham 
Offspring Study. Design and preliminary data. Prev Med 1975;4:518–525. 
9 Splansky GL, Corey D, Yang Q et al. The Third Generation Cohort of the National Heart, 
Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am 
J Epidemiol 2007;165:1328–1335. 
10 Carandang R, Seshadri S, Beiser A et al. Trends in incidence, lifetime risk, severity, and 30-
day mortality of stroke over the past 50 years. JAMA 2006;296:2939–2946.  
11 Seshadri S, Beiser A, Kelly-Hayes M et al. The lifetime risk of stroke: estimates from the 
Framingham Study. Stroke 2006;37:345–350.  
12 Wolf PA, Kannel WB, Dawber TR. Prospective investigations: the Framingham study and the 
epidemiology of stroke. Adv Neurol 1978;19:107–120. 
13 Psaty, B.M., et al., The risk of myocardial infarction associated with the combined use of 
estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154 :1333–9. 
14 Psaty, B.M., et al., The risk of myocardial infarction associated with antihypertensive drug 
therapies. JAMA, 1995;274 :620–5. 
15 Klungel, O.H., et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch 
Intern Med. 2001;161 :37–43. 
16 Price TR, Psaty BM, O'Leary D, et al. Assessment of cerebrovascular disease in the 
Cardiovascular Health Study. Ann Epidemiol. 1993;3: 504–507. 
17 Meschia JF, Nalls M, Matarin M, et al. Siblings with ischemic stroke study: results of a 
genome-wide scan for stroke loci. Stroke 2011; 42: 2726–32. 
18 Chen DT, Worrall BB, Brown RD, Jr,  et al. The impact of privacy protections on recruitment 
in a multicenter stroke genetics study. Neurology 2005; 64: 721–4. 
19   Meschia JF, Barrett KM, Chukwudelunzu F, et al. Interobserver agreement in the trial of org 
10172 in acute stroke treatment classification of stroke based on retrospective medical record review. J 
Stroke Cerebrovasc Dis 2006; 15: 266–72. 
20 Meschia JF, Brott TG, Brown RD,Jr, et al. The Ischemic Stroke Genetics Study (ISGS) 
Protocol. BMC Neurol 2003; 3: 4. 
21 Hofman A, van Duijn CM, Franco OH, et al. The Rotterdam Study: 2012 objectives and 
design update. Eur J Epidemiol 2011; 26: 657–86. 
22 Zacho J, Tybjærg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and 
ischemic vascular disease. N Engl J Med 2008; 359: 1897–908. 
23 Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjærg-Hansen A, Davey Smith G, 
Timpson NJ. The effect of elevated body mass index on ischemic heart disease risk: Causal estimates 
from a Mendelian randomisation approach. Plos Med 2012; 9: e1001212 
24 Deary IJ, Gow AJ, Taylor MD, et al. The Lothian Birth Cohort 1936: a study to examine 
influences on cognitive ageing from age 11 to age 70 and beyond. BMC Geriatrics 2007; 7: 28. 
25 Doney AS, Dannfald J, Kimber CH, et al. The FTO gene is associated with an atherogenic 
lipid profile and myocardial infarction in patients with type 2 diabetes: a Genetics of Diabetes Audit 
and Research Study in Tayside Scotland (Go-DARTS) study. Circ Cardiovasc Genet 2009; 2: 255–9. 
26 Morris AD, Boyle DI, MacAlpine R, et al. The diabetes audit and research in Tayside 
Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO 
Collaboration. BMJ 1997; 315: 524–8. 
27 Schmidt R, Lechner H, Fazekas F, et al. Assessment of cerebrovascular risk profiles in healthy 
persons: definition of research goals and the Austrian Stroke Prevention Study (ASPS). 
Neuroepidemiology. 1994; 13: 308–313 
28 Hallström B, Jönsson AC, Nerbrand C, Petersen B, Norrving B, Lindgren A. Lund stroke 
register: Hospitalization pattern and yield of different screening methods for first-ever stroke. Acta 
Neurol Scand. 2007; 115: 49–54 
29 Berger K, Stögbauer F, Stoll, M, et al. The glu298asp polymorphism in the nitric oxide 
synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control 
studies. Hum Genet 2007; 121: 169–78 
30 Vennemann MMT, Hummel T, Berger K: The association between smoking and smell and 
taste impairment in the general population. J Neurol 2008; 255; 1121–1126 
31 Krug T, Manso H, Gouveia L, et al. Kalirin: a novel genetic risk factor for ischemic stroke. 
Hum Genet 2010; 127: 513–23. 
32 Simons PC, Algra A, van de Laak MF, et al. Second manifestations of ARTerial disease 
(SMART) study: rationale and design. Eur J Epidemiol. 1999; 15: 773–781. 
33 Achterberg S, Cramer MJ, Kappelle LJ et al. Patients with coronary, cerebrovascular or 
peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART 
study. Eur J Cardiovasc Prev Rehabil. 2010; 17: 424–430. 
34 Spence JD, Howard VJ, Chambless LE, et al. Vitamin Intervention for Stroke Prevention 
(VISP) Trial: Rationale and Design. Neuroepidemiology, 2001; 20:16–25. 
35 Toole JF. Vitamin intervention for stroke prevention. J Neurol Sci 2002; 203-204: 121–4.  
36 Davies G, Tenesa A, Payton A, et al. Genome-wide association studies establish that human 
intelligence is highly heritable and polygenic. Mol. Psychiatry 2011; 16: 996–1005. 
 
  
Acknowledgements 
 
Wellcome Trust Case Control consortium 2 
The principal funding for this study was provided by the Wellcome Trust, as part of the Wellcome 
Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z).  
We also thank S. Bertrand, J. Bryant, S.L. Clark, J.S. Conquer, T. Dibling, J.C. Eldred, S. Gamble, C. 
Hind, M.L. Perez, C.R. Stribling, S. Taylor and A. Wilk of the Wellcome Trust Sanger Institute's 
Sample and Genotyping Facilities for technical assistance.  
We acknowledge use of the British 1958 Birth Cohort DNA collection, funded by the Medical 
Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02, and of the UK National 
Blood Service controls funded by the Wellcome Trust.  
 
 
Membership of Wellcome Trust Case Control Consortium 2 
Management Committee 
Peter Donnelly (Chair)1,2, Ines Barroso (Deputy Chair)3, Jenefer M Blackwell4, 5,  Elvira Bramon6 , 
Matthew A Brown7 , Juan P Casas8 , Aiden Corvin9, Panos Deloukas3, Audrey Duncanson10, Janusz 
Jankowski11, Hugh S Markus12, Christopher G Mathew13, Colin NA Palmer14, Robert Plomin15, Anna 
Rautanen1, Stephen J Sawcer16, Richard C Trembath13, Ananth C Viswanathan17, Nicholas W Wood18  
Data and Analysis Group 
Chris C A Spencer1, Gavin Band1, Céline Bellenguez1, Colin Freeman1, Garrett Hellenthal1, Eleni 
Giannoulatou1, Matti Pirinen1, Richard Pearson1, Amy Strange1, Zhan Su1, Damjan Vukcevic1, Peter 
Donnelly1,2  
DNA, Genotyping, Data QC and Informatics Group 
Cordelia Langford3, Sarah E Hunt3, Sarah Edkins3, Rhian Gwilliam3, Hannah Blackburn3, Suzannah J 
Bumpstead3, Serge Dronov3, Matthew Gillman3, Emma Gray3, Naomi Hammond3, Alagurevathi 
Jayakumar3, Owen T McCann3, Jennifer Liddle3, Simon C Potter3, Radhi Ravindrarajah3, Michelle 
Ricketts3, Matthew Waller3, Paul Weston3, Sara Widaa3, Pamela Whittaker3, Ines Barroso3, Panos 
Deloukas3.  
Publications Committee 
Christopher G Mathew (Chair)13, Jenefer M Blackwell4,5, Matthew A Brown7, Aiden Corvin9, Chris C 
A Spencer1    
 
 
1 Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 
7BN, UK; 2 Dept Statistics, University of Oxford, Oxford OX1 3TG, UK; 3 Wellcome Trust Sanger 
Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK; 4 Telethon Institute 
for Child Health Research, Centre for Child Health Research, University of Western Australia, 100 
Roberts Road, Subiaco, Western Australia 6008; 5 Cambridge Institute for Medical Research, 
University of Cambridge School of Clinical Medicine, Cambridge CB2 0XY, UK; 6 Department of 
Psychosis Studies, NIHR Biomedical Research Centre for Mental Health at the Institute of Psychiatry, 
King’s College London and The South London and Maudsley NHS Foundation Trust, Denmark Hill, 
London SE5 8AF, UK; 7 University of Queensland Diamantina Institute, Brisbane, Queensland, 
Australia; 8 Dept Epidemiology and Population Health, London School of Hygiene and Tropical 
Medicine, London WC1E 7HT and Dept Epidemiology and Public Health, University College London 
WC1E 6BT, UK; 9 Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, 
Trinity College Dublin, Dublin 2, Eire; 10 Molecular and Physiological Sciences, The Wellcome Trust, 
London NW1 2BE; 11 Department of Oncology, Old Road Campus, University of Oxford, Oxford 
OX3 7DQ, UK , Digestive Diseases Centre, Leicester Royal Infirmary, Leicester LE7 7HH, UK and 
Centre for Digestive Diseases, Queen Mary University of London, London E1 2AD, UK; 12 Clinical 
Neurosciences, St George's University of London, London SW17 0RE; 13 King’s College London 
Dept Medical and Molecular Genetics, King’s Health Partners, Guy’s Hospital, London SE1 9RT, UK; 
14 Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 15 
King’s College London Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, 
Denmark Hill, London SE5 8AF, UK; 16 University of Cambridge Dept Clinical Neurosciences, 
Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK; 17 NIHR Biomedical Research Centre for 
Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, 
London EC1V 2PD, UK; 18 Dept Molecular Neuroscience, Institute of Neurology, Queen Square, 
London WC1N 3BG, UK. 
  
The Australian Stroke Genetics Collaborative 
Jane M. Maguire, Ph.D. 
 School of Nursing and Midwifery, University of Newcastle, New South Wales, Australia 
John Attia, M.D. 
Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, 
University of Newcastle, New South Wales, Australia 
Rodney J. Scott, Ph.D. 
Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine, Hunter 
Medical Research Institute, Newcastle, New South Wales, Australia 
Lisa F. Lincz, Ph.D. 
Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Newcastle, 
Australia 
Pablo Moscato, Ph.D. 
Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine, Hunter 
Medical Research Institute, Newcastle, New South Wales, Australia 
Simon A. Koblar, M.D. 
Stroke Research Program, School of Medicine, University of Adelaide, South Australia, 
Australia 
Jim Jannes, M.D. 
Stroke Research Program, School of Medicine, University of Adelaide, South Australia, 
Australia 
Jonathan W. Sturm, M.D. 
Department of Neurosciences, Gosford Hospital, Central Coast Area Health, New South 
Wales, Australia 
Graeme J. Hankey, M.D. 
 Royal Perth Hospital, Perth, Western Australia, Australia 
Ross Baker, M.D. 
 Royal Perth Hospital, Perth, Western Australia, Australia 
Mark W. Parsons, M.D. 
Centre for Brain and Mental Health Research, University of Newcastle and Hunter Medical 
Research Institute, New South Wales, Australia 
Mark McEvoy, Ph.D. 
Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, 
University of Newcastle, New South Wales, Australia 
Roseanne Peel, M.Sc. 
Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, 
University of Newcastle, New South Wales, Australia 
Wayne Smith, Ph.D. 
 Hunter Medical Research Institute and University of Newcastle, New South Wales, Australia 
Martin D. Lewis, Ph.D.  
Stroke Research Program, School of Medicine, University of Adelaide, South Australia, 
Australia 
Tiffany-Jane Evans, B.Sc (Hons) 
Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine, Hunter 
Medical Research Institute, Newcastle, New South Wales, Australia 
Jonathan Golledge, M.D.  
Vascular Biology Unit, School of Medicine and Dentistry, James Cook University, 
Townsville, Queensland, Australia 
Erik Biros, Ph.D. 
Vascular Biology Unit, School of Medicine and Dentistry, James Cook University, 
Townsville, Queensland, Australia 
  
 
 
National Institutes of Health 
 
Luigi Ferrucci - Longitudinal Studies Section, National Institute on Aging, National Institutes of 
Health, Baltimore USA 
Andrew Singleton - Laboratory of Neurogenetics, National Institute on Aging, National Institutes of 
Health, Bethesda USA 
